SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19
In a phase 2 trial, outpatients with Covid-19 who received a single infusion of a 2800-mg dose of the neutralizing antibody LY-CoV555 had a greater reduction from baseline in viral load than those who received placebo. Hospitalization was less frequent among antibody-treated patients (1.6% vs. 6.3%)...
Saved in:
| Published in: | The New England journal of medicine Vol. 384; no. 3; pp. 229 - 237 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
United States
Massachusetts Medical Society
21.01.2021
|
| Subjects: | |
| ISSN: | 0028-4793, 1533-4406, 1533-4406 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | In a phase 2 trial, outpatients with Covid-19 who received a single infusion of a 2800-mg dose of the neutralizing antibody LY-CoV555 had a greater reduction from baseline in viral load than those who received placebo. Hospitalization was less frequent among antibody-treated patients (1.6% vs. 6.3%). |
|---|---|
| AbstractList | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (Covid-19), which is most frequently mild yet can be severe and life-threatening. Virus-neutralizing monoclonal antibodies are predicted to reduce viral load, ameliorate symptoms, and prevent hospitalization.BACKGROUNDSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (Covid-19), which is most frequently mild yet can be severe and life-threatening. Virus-neutralizing monoclonal antibodies are predicted to reduce viral load, ameliorate symptoms, and prevent hospitalization.In this ongoing phase 2 trial involving outpatients with recently diagnosed mild or moderate Covid-19, we randomly assigned 452 patients to receive a single intravenous infusion of neutralizing antibody LY-CoV555 in one of three doses (700 mg, 2800 mg, or 7000 mg) or placebo and evaluated the quantitative virologic end points and clinical outcomes. The primary outcome was the change from baseline in the viral load at day 11. The results of a preplanned interim analysis as of September 5, 2020, are reported here.METHODSIn this ongoing phase 2 trial involving outpatients with recently diagnosed mild or moderate Covid-19, we randomly assigned 452 patients to receive a single intravenous infusion of neutralizing antibody LY-CoV555 in one of three doses (700 mg, 2800 mg, or 7000 mg) or placebo and evaluated the quantitative virologic end points and clinical outcomes. The primary outcome was the change from baseline in the viral load at day 11. The results of a preplanned interim analysis as of September 5, 2020, are reported here.At the time of the interim analysis, the observed mean decrease from baseline in the log viral load for the entire population was -3.81, for an elimination of more than 99.97% of viral RNA. For patients who received the 2800-mg dose of LY-CoV555, the difference from placebo in the decrease from baseline was -0.53 (95% confidence interval [CI], -0.98 to -0.08; P = 0.02), for a viral load that was lower by a factor of 3.4. Smaller differences from placebo in the change from baseline were observed among the patients who received the 700-mg dose (-0.20; 95% CI, -0.66 to 0.25; P = 0.38) or the 7000-mg dose (0.09; 95% CI, -0.37 to 0.55; P = 0.70). On days 2 to 6, the patients who received LY-CoV555 had a slightly lower severity of symptoms than those who received placebo. The percentage of patients who had a Covid-19-related hospitalization or visit to an emergency department was 1.6% in the LY-CoV555 group and 6.3% in the placebo group.RESULTSAt the time of the interim analysis, the observed mean decrease from baseline in the log viral load for the entire population was -3.81, for an elimination of more than 99.97% of viral RNA. For patients who received the 2800-mg dose of LY-CoV555, the difference from placebo in the decrease from baseline was -0.53 (95% confidence interval [CI], -0.98 to -0.08; P = 0.02), for a viral load that was lower by a factor of 3.4. Smaller differences from placebo in the change from baseline were observed among the patients who received the 700-mg dose (-0.20; 95% CI, -0.66 to 0.25; P = 0.38) or the 7000-mg dose (0.09; 95% CI, -0.37 to 0.55; P = 0.70). On days 2 to 6, the patients who received LY-CoV555 had a slightly lower severity of symptoms than those who received placebo. The percentage of patients who had a Covid-19-related hospitalization or visit to an emergency department was 1.6% in the LY-CoV555 group and 6.3% in the placebo group.In this interim analysis of a phase 2 trial, one of three doses of neutralizing antibody LY-CoV555 appeared to accelerate the natural decline in viral load over time, whereas the other doses had not by day 11. (Funded by Eli Lilly; BLAZE-1 ClinicalTrials.gov number, NCT04427501.).CONCLUSIONSIn this interim analysis of a phase 2 trial, one of three doses of neutralizing antibody LY-CoV555 appeared to accelerate the natural decline in viral load over time, whereas the other doses had not by day 11. (Funded by Eli Lilly; BLAZE-1 ClinicalTrials.gov number, NCT04427501.). In a phase 2 trial, outpatients with Covid-19 who received a single infusion of a 2800-mg dose of the neutralizing antibody LY-CoV555 had a greater reduction from baseline in viral load than those who received placebo. Hospitalization was less frequent among antibody-treated patients (1.6% vs. 6.3%). BackgroundSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (Covid-19), which is most frequently mild yet can be severe and life-threatening. Virus-neutralizing monoclonal antibodies are predicted to reduce viral load, ameliorate symptoms, and prevent hospitalization.MethodsIn this ongoing phase 2 trial involving outpatients with recently diagnosed mild or moderate Covid-19, we randomly assigned 452 patients to receive a single intravenous infusion of neutralizing antibody LY-CoV555 in one of three doses (700 mg, 2800 mg, or 7000 mg) or placebo and evaluated the quantitative virologic end points and clinical outcomes. The primary outcome was the change from baseline in the viral load at day 11. The results of a preplanned interim analysis as of September 5, 2020, are reported here.ResultsAt the time of the interim analysis, the observed mean decrease from baseline in the log viral load for the entire population was −3.81, for an elimination of more than 99.97% of viral RNA. For patients who received the 2800-mg dose of LY-CoV555, the difference from placebo in the decrease from baseline was −0.53 (95% confidence interval [CI], −0.98 to −0.08; P=0.02), for a viral load that was lower by a factor of 3.4. Smaller differences from placebo in the change from baseline were observed among the patients who received the 700-mg dose (−0.20; 95% CI, −0.66 to 0.25; P=0.38) or the 7000-mg dose (0.09; 95% CI, −0.37 to 0.55; P=0.70). On days 2 to 6, the patients who received LY-CoV555 had a slightly lower severity of symptoms than those who received placebo. The percentage of patients who had a Covid-19–related hospitalization or visit to an emergency department was 1.6% in the LY-CoV555 group and 6.3% in the placebo group.ConclusionsIn this interim analysis of a phase 2 trial, one of three doses of neutralizing antibody LY-CoV555 appeared to accelerate the natural decline in viral load over time, whereas the other doses had not by day 11. (Funded by Eli Lilly; BLAZE-1 ClinicalTrials.gov number, NCT04427501.) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (Covid-19), which is most frequently mild yet can be severe and life-threatening. Virus-neutralizing monoclonal antibodies are predicted to reduce viral load, ameliorate symptoms, and prevent hospitalization. In this ongoing phase 2 trial involving outpatients with recently diagnosed mild or moderate Covid-19, we randomly assigned 452 patients to receive a single intravenous infusion of neutralizing antibody LY-CoV555 in one of three doses (700 mg, 2800 mg, or 7000 mg) or placebo and evaluated the quantitative virologic end points and clinical outcomes. The primary outcome was the change from baseline in the viral load at day 11. The results of a preplanned interim analysis as of September 5, 2020, are reported here. At the time of the interim analysis, the observed mean decrease from baseline in the log viral load for the entire population was -3.81, for an elimination of more than 99.97% of viral RNA. For patients who received the 2800-mg dose of LY-CoV555, the difference from placebo in the decrease from baseline was -0.53 (95% confidence interval [CI], -0.98 to -0.08; P = 0.02), for a viral load that was lower by a factor of 3.4. Smaller differences from placebo in the change from baseline were observed among the patients who received the 700-mg dose (-0.20; 95% CI, -0.66 to 0.25; P = 0.38) or the 7000-mg dose (0.09; 95% CI, -0.37 to 0.55; P = 0.70). On days 2 to 6, the patients who received LY-CoV555 had a slightly lower severity of symptoms than those who received placebo. The percentage of patients who had a Covid-19-related hospitalization or visit to an emergency department was 1.6% in the LY-CoV555 group and 6.3% in the placebo group. In this interim analysis of a phase 2 trial, one of three doses of neutralizing antibody LY-CoV555 appeared to accelerate the natural decline in viral load over time, whereas the other doses had not by day 11. (Funded by Eli Lilly; BLAZE-1 ClinicalTrials.gov number, NCT04427501.). |
| Author | Sabo, Janelle Boscia, Joseph Van Naarden, Jacob Durante, Michael Huhn, Gregory Shen, Lei Gottlieb, Robert L Stosor, Valentina Nirula, Ajay Custer, Kenneth L Skovronsky, Daniel M Schade, Andrew E Heller, Barry Oakley, Gerard Adams, Andrew C Patel, Dipak R Morris, Jason Cardona, Jose Mocherla, Bharat Chen, Peter Shawa, Imad Klekotka, Paul |
| Author_xml | – sequence: 1 givenname: Peter surname: Chen fullname: Chen, Peter organization: From the Department of Medicine, Women’s Guild Lung Institute, Cedars–Sinai Medical Center, Los Angeles (P.C.), and Long Beach Clinical Trials, Long Beach (B.H.) — both in California; Eli Lilly, Indianapolis (A.N., A.C.A., J.V.N., K.L.C., L.S., M.D., G.O., A.E.S., J.S., D.R.P., P.K., D.M.S.), and Franciscan Health, Greenwood (I.S.) — both in Indiana; Baylor University Medical Center and Baylor Scott and White Research Institute, Dallas (R.L.G.); Vitalink Research, Union, SC (J.B.); Imperial Health, Lake Charles, LA (J.M.); Cook County Health (G.H.) and Northwestern University Feinberg School of Medicine (V.S.), Chicago; Indago Research and Health Center, Hialeah, FL (J.C.); and Las Vegas Medical Research Center, Las Vegas (B.M.) – sequence: 2 givenname: Ajay surname: Nirula fullname: Nirula, Ajay organization: From the Department of Medicine, Women’s Guild Lung Institute, Cedars–Sinai Medical Center, Los Angeles (P.C.), and Long Beach Clinical Trials, Long Beach (B.H.) — both in California; Eli Lilly, Indianapolis (A.N., A.C.A., J.V.N., K.L.C., L.S., M.D., G.O., A.E.S., J.S., D.R.P., P.K., D.M.S.), and Franciscan Health, Greenwood (I.S.) — both in Indiana; Baylor University Medical Center and Baylor Scott and White Research Institute, Dallas (R.L.G.); Vitalink Research, Union, SC (J.B.); Imperial Health, Lake Charles, LA (J.M.); Cook County Health (G.H.) and Northwestern University Feinberg School of Medicine (V.S.), Chicago; Indago Research and Health Center, Hialeah, FL (J.C.); and Las Vegas Medical Research Center, Las Vegas (B.M.) – sequence: 3 givenname: Barry surname: Heller fullname: Heller, Barry organization: From the Department of Medicine, Women’s Guild Lung Institute, Cedars–Sinai Medical Center, Los Angeles (P.C.), and Long Beach Clinical Trials, Long Beach (B.H.) — both in California; Eli Lilly, Indianapolis (A.N., A.C.A., J.V.N., K.L.C., L.S., M.D., G.O., A.E.S., J.S., D.R.P., P.K., D.M.S.), and Franciscan Health, Greenwood (I.S.) — both in Indiana; Baylor University Medical Center and Baylor Scott and White Research Institute, Dallas (R.L.G.); Vitalink Research, Union, SC (J.B.); Imperial Health, Lake Charles, LA (J.M.); Cook County Health (G.H.) and Northwestern University Feinberg School of Medicine (V.S.), Chicago; Indago Research and Health Center, Hialeah, FL (J.C.); and Las Vegas Medical Research Center, Las Vegas (B.M.) – sequence: 4 givenname: Robert L surname: Gottlieb fullname: Gottlieb, Robert L organization: From the Department of Medicine, Women’s Guild Lung Institute, Cedars–Sinai Medical Center, Los Angeles (P.C.), and Long Beach Clinical Trials, Long Beach (B.H.) — both in California; Eli Lilly, Indianapolis (A.N., A.C.A., J.V.N., K.L.C., L.S., M.D., G.O., A.E.S., J.S., D.R.P., P.K., D.M.S.), and Franciscan Health, Greenwood (I.S.) — both in Indiana; Baylor University Medical Center and Baylor Scott and White Research Institute, Dallas (R.L.G.); Vitalink Research, Union, SC (J.B.); Imperial Health, Lake Charles, LA (J.M.); Cook County Health (G.H.) and Northwestern University Feinberg School of Medicine (V.S.), Chicago; Indago Research and Health Center, Hialeah, FL (J.C.); and Las Vegas Medical Research Center, Las Vegas (B.M.) – sequence: 5 givenname: Joseph surname: Boscia fullname: Boscia, Joseph organization: From the Department of Medicine, Women’s Guild Lung Institute, Cedars–Sinai Medical Center, Los Angeles (P.C.), and Long Beach Clinical Trials, Long Beach (B.H.) — both in California; Eli Lilly, Indianapolis (A.N., A.C.A., J.V.N., K.L.C., L.S., M.D., G.O., A.E.S., J.S., D.R.P., P.K., D.M.S.), and Franciscan Health, Greenwood (I.S.) — both in Indiana; Baylor University Medical Center and Baylor Scott and White Research Institute, Dallas (R.L.G.); Vitalink Research, Union, SC (J.B.); Imperial Health, Lake Charles, LA (J.M.); Cook County Health (G.H.) and Northwestern University Feinberg School of Medicine (V.S.), Chicago; Indago Research and Health Center, Hialeah, FL (J.C.); and Las Vegas Medical Research Center, Las Vegas (B.M.) – sequence: 6 givenname: Jason surname: Morris fullname: Morris, Jason organization: From the Department of Medicine, Women’s Guild Lung Institute, Cedars–Sinai Medical Center, Los Angeles (P.C.), and Long Beach Clinical Trials, Long Beach (B.H.) — both in California; Eli Lilly, Indianapolis (A.N., A.C.A., J.V.N., K.L.C., L.S., M.D., G.O., A.E.S., J.S., D.R.P., P.K., D.M.S.), and Franciscan Health, Greenwood (I.S.) — both in Indiana; Baylor University Medical Center and Baylor Scott and White Research Institute, Dallas (R.L.G.); Vitalink Research, Union, SC (J.B.); Imperial Health, Lake Charles, LA (J.M.); Cook County Health (G.H.) and Northwestern University Feinberg School of Medicine (V.S.), Chicago; Indago Research and Health Center, Hialeah, FL (J.C.); and Las Vegas Medical Research Center, Las Vegas (B.M.) – sequence: 7 givenname: Gregory surname: Huhn fullname: Huhn, Gregory organization: From the Department of Medicine, Women’s Guild Lung Institute, Cedars–Sinai Medical Center, Los Angeles (P.C.), and Long Beach Clinical Trials, Long Beach (B.H.) — both in California; Eli Lilly, Indianapolis (A.N., A.C.A., J.V.N., K.L.C., L.S., M.D., G.O., A.E.S., J.S., D.R.P., P.K., D.M.S.), and Franciscan Health, Greenwood (I.S.) — both in Indiana; Baylor University Medical Center and Baylor Scott and White Research Institute, Dallas (R.L.G.); Vitalink Research, Union, SC (J.B.); Imperial Health, Lake Charles, LA (J.M.); Cook County Health (G.H.) and Northwestern University Feinberg School of Medicine (V.S.), Chicago; Indago Research and Health Center, Hialeah, FL (J.C.); and Las Vegas Medical Research Center, Las Vegas (B.M.) – sequence: 8 givenname: Jose surname: Cardona fullname: Cardona, Jose organization: From the Department of Medicine, Women’s Guild Lung Institute, Cedars–Sinai Medical Center, Los Angeles (P.C.), and Long Beach Clinical Trials, Long Beach (B.H.) — both in California; Eli Lilly, Indianapolis (A.N., A.C.A., J.V.N., K.L.C., L.S., M.D., G.O., A.E.S., J.S., D.R.P., P.K., D.M.S.), and Franciscan Health, Greenwood (I.S.) — both in Indiana; Baylor University Medical Center and Baylor Scott and White Research Institute, Dallas (R.L.G.); Vitalink Research, Union, SC (J.B.); Imperial Health, Lake Charles, LA (J.M.); Cook County Health (G.H.) and Northwestern University Feinberg School of Medicine (V.S.), Chicago; Indago Research and Health Center, Hialeah, FL (J.C.); and Las Vegas Medical Research Center, Las Vegas (B.M.) – sequence: 9 givenname: Bharat surname: Mocherla fullname: Mocherla, Bharat organization: From the Department of Medicine, Women’s Guild Lung Institute, Cedars–Sinai Medical Center, Los Angeles (P.C.), and Long Beach Clinical Trials, Long Beach (B.H.) — both in California; Eli Lilly, Indianapolis (A.N., A.C.A., J.V.N., K.L.C., L.S., M.D., G.O., A.E.S., J.S., D.R.P., P.K., D.M.S.), and Franciscan Health, Greenwood (I.S.) — both in Indiana; Baylor University Medical Center and Baylor Scott and White Research Institute, Dallas (R.L.G.); Vitalink Research, Union, SC (J.B.); Imperial Health, Lake Charles, LA (J.M.); Cook County Health (G.H.) and Northwestern University Feinberg School of Medicine (V.S.), Chicago; Indago Research and Health Center, Hialeah, FL (J.C.); and Las Vegas Medical Research Center, Las Vegas (B.M.) – sequence: 10 givenname: Valentina surname: Stosor fullname: Stosor, Valentina organization: From the Department of Medicine, Women’s Guild Lung Institute, Cedars–Sinai Medical Center, Los Angeles (P.C.), and Long Beach Clinical Trials, Long Beach (B.H.) — both in California; Eli Lilly, Indianapolis (A.N., A.C.A., J.V.N., K.L.C., L.S., M.D., G.O., A.E.S., J.S., D.R.P., P.K., D.M.S.), and Franciscan Health, Greenwood (I.S.) — both in Indiana; Baylor University Medical Center and Baylor Scott and White Research Institute, Dallas (R.L.G.); Vitalink Research, Union, SC (J.B.); Imperial Health, Lake Charles, LA (J.M.); Cook County Health (G.H.) and Northwestern University Feinberg School of Medicine (V.S.), Chicago; Indago Research and Health Center, Hialeah, FL (J.C.); and Las Vegas Medical Research Center, Las Vegas (B.M.) – sequence: 11 givenname: Imad surname: Shawa fullname: Shawa, Imad organization: From the Department of Medicine, Women’s Guild Lung Institute, Cedars–Sinai Medical Center, Los Angeles (P.C.), and Long Beach Clinical Trials, Long Beach (B.H.) — both in California; Eli Lilly, Indianapolis (A.N., A.C.A., J.V.N., K.L.C., L.S., M.D., G.O., A.E.S., J.S., D.R.P., P.K., D.M.S.), and Franciscan Health, Greenwood (I.S.) — both in Indiana; Baylor University Medical Center and Baylor Scott and White Research Institute, Dallas (R.L.G.); Vitalink Research, Union, SC (J.B.); Imperial Health, Lake Charles, LA (J.M.); Cook County Health (G.H.) and Northwestern University Feinberg School of Medicine (V.S.), Chicago; Indago Research and Health Center, Hialeah, FL (J.C.); and Las Vegas Medical Research Center, Las Vegas (B.M.) – sequence: 12 givenname: Andrew C surname: Adams fullname: Adams, Andrew C organization: From the Department of Medicine, Women’s Guild Lung Institute, Cedars–Sinai Medical Center, Los Angeles (P.C.), and Long Beach Clinical Trials, Long Beach (B.H.) — both in California; Eli Lilly, Indianapolis (A.N., A.C.A., J.V.N., K.L.C., L.S., M.D., G.O., A.E.S., J.S., D.R.P., P.K., D.M.S.), and Franciscan Health, Greenwood (I.S.) — both in Indiana; Baylor University Medical Center and Baylor Scott and White Research Institute, Dallas (R.L.G.); Vitalink Research, Union, SC (J.B.); Imperial Health, Lake Charles, LA (J.M.); Cook County Health (G.H.) and Northwestern University Feinberg School of Medicine (V.S.), Chicago; Indago Research and Health Center, Hialeah, FL (J.C.); and Las Vegas Medical Research Center, Las Vegas (B.M.) – sequence: 13 givenname: Jacob surname: Van Naarden fullname: Van Naarden, Jacob organization: From the Department of Medicine, Women’s Guild Lung Institute, Cedars–Sinai Medical Center, Los Angeles (P.C.), and Long Beach Clinical Trials, Long Beach (B.H.) — both in California; Eli Lilly, Indianapolis (A.N., A.C.A., J.V.N., K.L.C., L.S., M.D., G.O., A.E.S., J.S., D.R.P., P.K., D.M.S.), and Franciscan Health, Greenwood (I.S.) — both in Indiana; Baylor University Medical Center and Baylor Scott and White Research Institute, Dallas (R.L.G.); Vitalink Research, Union, SC (J.B.); Imperial Health, Lake Charles, LA (J.M.); Cook County Health (G.H.) and Northwestern University Feinberg School of Medicine (V.S.), Chicago; Indago Research and Health Center, Hialeah, FL (J.C.); and Las Vegas Medical Research Center, Las Vegas (B.M.) – sequence: 14 givenname: Kenneth L surname: Custer fullname: Custer, Kenneth L organization: From the Department of Medicine, Women’s Guild Lung Institute, Cedars–Sinai Medical Center, Los Angeles (P.C.), and Long Beach Clinical Trials, Long Beach (B.H.) — both in California; Eli Lilly, Indianapolis (A.N., A.C.A., J.V.N., K.L.C., L.S., M.D., G.O., A.E.S., J.S., D.R.P., P.K., D.M.S.), and Franciscan Health, Greenwood (I.S.) — both in Indiana; Baylor University Medical Center and Baylor Scott and White Research Institute, Dallas (R.L.G.); Vitalink Research, Union, SC (J.B.); Imperial Health, Lake Charles, LA (J.M.); Cook County Health (G.H.) and Northwestern University Feinberg School of Medicine (V.S.), Chicago; Indago Research and Health Center, Hialeah, FL (J.C.); and Las Vegas Medical Research Center, Las Vegas (B.M.) – sequence: 15 givenname: Lei surname: Shen fullname: Shen, Lei organization: From the Department of Medicine, Women’s Guild Lung Institute, Cedars–Sinai Medical Center, Los Angeles (P.C.), and Long Beach Clinical Trials, Long Beach (B.H.) — both in California; Eli Lilly, Indianapolis (A.N., A.C.A., J.V.N., K.L.C., L.S., M.D., G.O., A.E.S., J.S., D.R.P., P.K., D.M.S.), and Franciscan Health, Greenwood (I.S.) — both in Indiana; Baylor University Medical Center and Baylor Scott and White Research Institute, Dallas (R.L.G.); Vitalink Research, Union, SC (J.B.); Imperial Health, Lake Charles, LA (J.M.); Cook County Health (G.H.) and Northwestern University Feinberg School of Medicine (V.S.), Chicago; Indago Research and Health Center, Hialeah, FL (J.C.); and Las Vegas Medical Research Center, Las Vegas (B.M.) – sequence: 16 givenname: Michael surname: Durante fullname: Durante, Michael organization: From the Department of Medicine, Women’s Guild Lung Institute, Cedars–Sinai Medical Center, Los Angeles (P.C.), and Long Beach Clinical Trials, Long Beach (B.H.) — both in California; Eli Lilly, Indianapolis (A.N., A.C.A., J.V.N., K.L.C., L.S., M.D., G.O., A.E.S., J.S., D.R.P., P.K., D.M.S.), and Franciscan Health, Greenwood (I.S.) — both in Indiana; Baylor University Medical Center and Baylor Scott and White Research Institute, Dallas (R.L.G.); Vitalink Research, Union, SC (J.B.); Imperial Health, Lake Charles, LA (J.M.); Cook County Health (G.H.) and Northwestern University Feinberg School of Medicine (V.S.), Chicago; Indago Research and Health Center, Hialeah, FL (J.C.); and Las Vegas Medical Research Center, Las Vegas (B.M.) – sequence: 17 givenname: Gerard surname: Oakley fullname: Oakley, Gerard organization: From the Department of Medicine, Women’s Guild Lung Institute, Cedars–Sinai Medical Center, Los Angeles (P.C.), and Long Beach Clinical Trials, Long Beach (B.H.) — both in California; Eli Lilly, Indianapolis (A.N., A.C.A., J.V.N., K.L.C., L.S., M.D., G.O., A.E.S., J.S., D.R.P., P.K., D.M.S.), and Franciscan Health, Greenwood (I.S.) — both in Indiana; Baylor University Medical Center and Baylor Scott and White Research Institute, Dallas (R.L.G.); Vitalink Research, Union, SC (J.B.); Imperial Health, Lake Charles, LA (J.M.); Cook County Health (G.H.) and Northwestern University Feinberg School of Medicine (V.S.), Chicago; Indago Research and Health Center, Hialeah, FL (J.C.); and Las Vegas Medical Research Center, Las Vegas (B.M.) – sequence: 18 givenname: Andrew E surname: Schade fullname: Schade, Andrew E organization: From the Department of Medicine, Women’s Guild Lung Institute, Cedars–Sinai Medical Center, Los Angeles (P.C.), and Long Beach Clinical Trials, Long Beach (B.H.) — both in California; Eli Lilly, Indianapolis (A.N., A.C.A., J.V.N., K.L.C., L.S., M.D., G.O., A.E.S., J.S., D.R.P., P.K., D.M.S.), and Franciscan Health, Greenwood (I.S.) — both in Indiana; Baylor University Medical Center and Baylor Scott and White Research Institute, Dallas (R.L.G.); Vitalink Research, Union, SC (J.B.); Imperial Health, Lake Charles, LA (J.M.); Cook County Health (G.H.) and Northwestern University Feinberg School of Medicine (V.S.), Chicago; Indago Research and Health Center, Hialeah, FL (J.C.); and Las Vegas Medical Research Center, Las Vegas (B.M.) – sequence: 19 givenname: Janelle surname: Sabo fullname: Sabo, Janelle organization: From the Department of Medicine, Women’s Guild Lung Institute, Cedars–Sinai Medical Center, Los Angeles (P.C.), and Long Beach Clinical Trials, Long Beach (B.H.) — both in California; Eli Lilly, Indianapolis (A.N., A.C.A., J.V.N., K.L.C., L.S., M.D., G.O., A.E.S., J.S., D.R.P., P.K., D.M.S.), and Franciscan Health, Greenwood (I.S.) — both in Indiana; Baylor University Medical Center and Baylor Scott and White Research Institute, Dallas (R.L.G.); Vitalink Research, Union, SC (J.B.); Imperial Health, Lake Charles, LA (J.M.); Cook County Health (G.H.) and Northwestern University Feinberg School of Medicine (V.S.), Chicago; Indago Research and Health Center, Hialeah, FL (J.C.); and Las Vegas Medical Research Center, Las Vegas (B.M.) – sequence: 20 givenname: Dipak R surname: Patel fullname: Patel, Dipak R organization: From the Department of Medicine, Women’s Guild Lung Institute, Cedars–Sinai Medical Center, Los Angeles (P.C.), and Long Beach Clinical Trials, Long Beach (B.H.) — both in California; Eli Lilly, Indianapolis (A.N., A.C.A., J.V.N., K.L.C., L.S., M.D., G.O., A.E.S., J.S., D.R.P., P.K., D.M.S.), and Franciscan Health, Greenwood (I.S.) — both in Indiana; Baylor University Medical Center and Baylor Scott and White Research Institute, Dallas (R.L.G.); Vitalink Research, Union, SC (J.B.); Imperial Health, Lake Charles, LA (J.M.); Cook County Health (G.H.) and Northwestern University Feinberg School of Medicine (V.S.), Chicago; Indago Research and Health Center, Hialeah, FL (J.C.); and Las Vegas Medical Research Center, Las Vegas (B.M.) – sequence: 21 givenname: Paul surname: Klekotka fullname: Klekotka, Paul organization: From the Department of Medicine, Women’s Guild Lung Institute, Cedars–Sinai Medical Center, Los Angeles (P.C.), and Long Beach Clinical Trials, Long Beach (B.H.) — both in California; Eli Lilly, Indianapolis (A.N., A.C.A., J.V.N., K.L.C., L.S., M.D., G.O., A.E.S., J.S., D.R.P., P.K., D.M.S.), and Franciscan Health, Greenwood (I.S.) — both in Indiana; Baylor University Medical Center and Baylor Scott and White Research Institute, Dallas (R.L.G.); Vitalink Research, Union, SC (J.B.); Imperial Health, Lake Charles, LA (J.M.); Cook County Health (G.H.) and Northwestern University Feinberg School of Medicine (V.S.), Chicago; Indago Research and Health Center, Hialeah, FL (J.C.); and Las Vegas Medical Research Center, Las Vegas (B.M.) – sequence: 22 givenname: Daniel M surname: Skovronsky fullname: Skovronsky, Daniel M organization: From the Department of Medicine, Women’s Guild Lung Institute, Cedars–Sinai Medical Center, Los Angeles (P.C.), and Long Beach Clinical Trials, Long Beach (B.H.) — both in California; Eli Lilly, Indianapolis (A.N., A.C.A., J.V.N., K.L.C., L.S., M.D., G.O., A.E.S., J.S., D.R.P., P.K., D.M.S.), and Franciscan Health, Greenwood (I.S.) — both in Indiana; Baylor University Medical Center and Baylor Scott and White Research Institute, Dallas (R.L.G.); Vitalink Research, Union, SC (J.B.); Imperial Health, Lake Charles, LA (J.M.); Cook County Health (G.H.) and Northwestern University Feinberg School of Medicine (V.S.), Chicago; Indago Research and Health Center, Hialeah, FL (J.C.); and Las Vegas Medical Research Center, Las Vegas (B.M.) |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33113295$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1kd9LHDEQx4NY6mn72NeyUAq-xOZ3Ni-F47D-4KpQf4BPIbub1Ry7ybnJKvrXm-OsqOC8zMB85st3ZrbBpg_eAvANoz2MuPh1sn_8NxiCiCqZ2gATzCmFjCGxCSYIkRIyqegW2I5xgXJgpj6DLUoxpkTxCTg4m_47g7NwCUlxYsc0mM49On9dTH1yVWgeivnVqs05L5wvTse0NMlZn2Jx79JNMQt3roFYfQGfWtNF-_U574CLP_vns0M4Pz04mk3nsGaSJsgrgivFhWhRy1SVa2sYJqhuBMPcSMNbWZmmJUY2teQcWaZkg2tsGWlL1dAd8Hutuxyr3jZ1dpIt6-XgejM86GCcftvx7kZfhzstBROC8Cyw-ywwhNvRxqR7F2vbdcbbMEZNGOclYxypjP54hy7COPi8XqakYkKRciX4_bWjFyv_b5wBuAbqIcQ42PYFwUivfqjf_DDz9B1fu5SPHlYLue7DqZ_rqb6P2ttF_wH3BFcLqIA |
| CitedBy_id | crossref_primary_10_1056_NEJMoa2035002 crossref_primary_10_1016_j_copbio_2022_102798 crossref_primary_10_1080_21645515_2021_1985891 crossref_primary_10_1126_scitranslmed_abi7826 crossref_primary_10_3389_fmed_2022_934169 crossref_primary_10_2196_25500 crossref_primary_10_1080_17460441_2021_1960819 crossref_primary_10_1093_pcmedi_pbae015 crossref_primary_10_1038_s42003_023_04589_5 crossref_primary_10_1128_aac_02045_21 crossref_primary_10_1016_j_ejca_2021_01_046 crossref_primary_10_7326_M22_1286 crossref_primary_10_12998_wjcc_v11_i10_2168 crossref_primary_10_1515_med_2023_0867 crossref_primary_10_1016_S2352_3018_21_00070_9 crossref_primary_10_3390_vaccines9080914 crossref_primary_10_1007_s11684_023_1021_y crossref_primary_10_1186_s12879_024_09022_8 crossref_primary_10_3390_v13030516 crossref_primary_10_1002_cpt_2376 crossref_primary_10_1038_s41392_021_00756_4 crossref_primary_10_1371_journal_ppat_1011532 crossref_primary_10_1002_ccr3_8162 crossref_primary_10_3389_fimmu_2024_1374913 crossref_primary_10_1038_s41586_021_03312_w crossref_primary_10_1080_22221751_2021_1898291 crossref_primary_10_7759_cureus_17672 crossref_primary_10_1016_S2213_2600_22_00044_3 crossref_primary_10_1126_sciimmunol_ade0958 crossref_primary_10_3390_cancers14153711 crossref_primary_10_2147_JIR_S306849 crossref_primary_10_1016_S2665_9913_21_00077_1 crossref_primary_10_1016_j_ijid_2021_01_035 crossref_primary_10_3390_v13040539 crossref_primary_10_1007_s40620_022_01449_z crossref_primary_10_12998_wjcc_v11_i10_2140 crossref_primary_10_1016_j_transci_2021_103161 crossref_primary_10_3390_biomedicines10030533 crossref_primary_10_1186_s12979_021_00248_7 crossref_primary_10_1097_GRF_0000000000000670 crossref_primary_10_3233_HAB_200441 crossref_primary_10_1080_10428194_2021_1897808 crossref_primary_10_1016_j_matt_2021_04_005 crossref_primary_10_1038_s41392_024_01917_x crossref_primary_10_2147_JMDH_S385050 crossref_primary_10_3390_v16101542 crossref_primary_10_7705_biomedica_6862 crossref_primary_10_1038_s41598_021_82932_8 crossref_primary_10_1016_j_cell_2021_05_005 crossref_primary_10_1056_NEJMe2034495 crossref_primary_10_1038_s41598_023_41051_2 crossref_primary_10_3390_v13091706 crossref_primary_10_1097_MCP_0000000000001214 crossref_primary_10_1182_blood_2021012248 crossref_primary_10_3390_vaccines11091472 crossref_primary_10_1093_infdis_jiab355 crossref_primary_10_1186_s12929_020_00703_5 crossref_primary_10_1007_s13181_023_00931_9 crossref_primary_10_1038_s42003_022_03739_5 crossref_primary_10_1038_s41392_021_00810_1 crossref_primary_10_1016_j_jaip_2021_10_073 crossref_primary_10_1007_s15010_022_01825_8 crossref_primary_10_1126_science_abn9649 crossref_primary_10_1016_j_ebiom_2022_103944 crossref_primary_10_3389_fimmu_2021_669339 crossref_primary_10_1128_mSystems_00233_21 crossref_primary_10_1007_s15010_021_01645_2 crossref_primary_10_1016_j_jnma_2021_08_036 crossref_primary_10_3389_fimmu_2022_1053437 crossref_primary_10_3390_ph15121472 crossref_primary_10_7326_M22_3428 crossref_primary_10_3389_fimmu_2021_692598 crossref_primary_10_1016_j_jmb_2021_167391 crossref_primary_10_1093_milmed_usab415 crossref_primary_10_3389_fimmu_2022_814365 crossref_primary_10_1002_prp2_1036 crossref_primary_10_1002_hon_2974 crossref_primary_10_1016_j_virs_2022_12_007 crossref_primary_10_1016_j_jmb_2021_167155 crossref_primary_10_1038_s41579_023_01001_1 crossref_primary_10_1126_science_abg2294 crossref_primary_10_3389_fimmu_2022_825256 crossref_primary_10_1016_j_celrep_2024_114076 crossref_primary_10_1186_s43556_022_00077_0 crossref_primary_10_1097_QAI_0000000000002892 crossref_primary_10_3390_pathogens11020275 crossref_primary_10_1016_j_jaip_2023_07_045 crossref_primary_10_3390_vaccines9030238 crossref_primary_10_1080_22221751_2021_1960900 crossref_primary_10_3233_HAB_230017 crossref_primary_10_3389_fimmu_2021_708848 crossref_primary_10_3390_nu13061760 crossref_primary_10_1016_j_ogc_2022_10_018 crossref_primary_10_1080_1120009X_2023_2289269 crossref_primary_10_1007_s40199_021_00422_8 crossref_primary_10_1093_infdis_jiab380 crossref_primary_10_1016_j_transproceed_2021_03_010 crossref_primary_10_1016_j_intimp_2022_108786 crossref_primary_10_1016_j_immuni_2021_08_013 crossref_primary_10_1128_jvi_00465_25 crossref_primary_10_3390_v14102121 crossref_primary_10_1007_s11427_020_1859_y crossref_primary_10_3390_ijms25105499 crossref_primary_10_1016_j_immuni_2021_08_016 crossref_primary_10_1016_j_immuni_2021_08_015 crossref_primary_10_3390_jcm10081586 crossref_primary_10_1073_pnas_2017962118 crossref_primary_10_1016_j_emc_2021_08_011 crossref_primary_10_3390_v14020186 crossref_primary_10_1007_s42399_021_00827_1 crossref_primary_10_1177_23743735221105673 crossref_primary_10_1080_08998280_2021_1925049 crossref_primary_10_1001_jamanetworkopen_2023_9694 crossref_primary_10_3389_fphar_2022_971890 crossref_primary_10_1177_1357633X221086067 crossref_primary_10_1111_tid_14006 crossref_primary_10_1136_gutjnl_2021_324276 crossref_primary_10_1017_S0950268822001078 crossref_primary_10_1016_j_tem_2021_08_011 crossref_primary_10_1371_journal_pcbi_1009380 crossref_primary_10_7326_M21_3669 crossref_primary_10_1093_infdis_jiad300 crossref_primary_10_1186_s12929_021_00784_w crossref_primary_10_36303_SAGP_2020_1_5_0048 crossref_primary_10_1016_j_tibs_2021_10_005 crossref_primary_10_1007_s11912_021_01111_0 crossref_primary_10_1038_s41577_021_00542_x crossref_primary_10_1016_j_jemermed_2021_07_025 crossref_primary_10_1073_pnas_2021615118 crossref_primary_10_1177_87551225221080027 crossref_primary_10_3390_brainsci12020190 crossref_primary_10_1016_j_jvacx_2025_100644 crossref_primary_10_1016_S2665_9913_21_00062_X crossref_primary_10_3389_fimmu_2021_761250 crossref_primary_10_1093_infdis_jiab377 crossref_primary_10_1016_j_transproceed_2021_03_008 crossref_primary_10_3389_frtra_2024_1305152 crossref_primary_10_3390_v15071504 crossref_primary_10_1073_pnas_2111600119 crossref_primary_10_1371_journal_pone_0324242 crossref_primary_10_1371_journal_pone_0304477 crossref_primary_10_1016_j_ijid_2024_107285 crossref_primary_10_3389_fimmu_2021_631139 crossref_primary_10_5802_crbiol_38 crossref_primary_10_1097_TP_0000000000003953 crossref_primary_10_1186_s12879_022_07819_z crossref_primary_10_1038_s41467_021_24963_3 crossref_primary_10_1093_ofid_ofab331 crossref_primary_10_1002_jcph_1820 crossref_primary_10_1002_jcph_1822 crossref_primary_10_1097_MCP_0000000000000766 crossref_primary_10_1080_14712598_2021_1985458 crossref_primary_10_1093_ofid_ofac411 crossref_primary_10_1093_ofid_ofab315 crossref_primary_10_3390_vaccines10040608 crossref_primary_10_1007_s10787_022_01105_9 crossref_primary_10_1093_ofid_ofac406 crossref_primary_10_3390_diagnostics12010205 crossref_primary_10_1016_j_chom_2021_12_010 crossref_primary_10_1111_jgs_17308 crossref_primary_10_1126_sciimmunol_abl4340 crossref_primary_10_1007_s12016_021_08912_y crossref_primary_10_3389_fmed_2022_811004 crossref_primary_10_1016_j_cct_2021_106625 crossref_primary_10_1016_j_cmi_2025_02_002 crossref_primary_10_1146_annurev_med_042420_113838 crossref_primary_10_3389_fimmu_2022_992787 crossref_primary_10_3390_vaccines10071103 crossref_primary_10_1007_s40121_022_00681_1 crossref_primary_10_3390_jpm11080709 crossref_primary_10_3390_ijms23116078 crossref_primary_10_1128_aac_00452_22 crossref_primary_10_1093_ofid_ofab305 crossref_primary_10_1093_ofid_ofab546 crossref_primary_10_1093_ofid_ofab313 crossref_primary_10_1016_S2352_3026_21_00073_9 crossref_primary_10_1080_22221751_2021_1942227 crossref_primary_10_5582_bst_2021_01092 crossref_primary_10_3389_fimmu_2022_833715 crossref_primary_10_1136_bmjopen_2022_063436 crossref_primary_10_1002_jmv_29252 crossref_primary_10_1016_j_intimp_2021_108200 crossref_primary_10_3390_v13060963 crossref_primary_10_1177_00333549211023267 crossref_primary_10_3390_v13010029 crossref_primary_10_1002_advs_202102330 crossref_primary_10_1093_cid_ciab374 crossref_primary_10_1016_j_transproceed_2021_02_014 crossref_primary_10_1016_j_transproceed_2021_02_015 crossref_primary_10_1017_cts_2022_526 crossref_primary_10_1177_02666669251327350 crossref_primary_10_3389_fimmu_2021_772320 crossref_primary_10_1038_s41467_024_46443_0 crossref_primary_10_1016_j_intimp_2021_108215 crossref_primary_10_3390_biomedicines13081801 crossref_primary_10_3390_jcm10040779 crossref_primary_10_3390_v16060923 crossref_primary_10_1016_j_jep_2023_117535 crossref_primary_10_4049_jimmunol_2300675 crossref_primary_10_3390_antiox10060881 crossref_primary_10_1016_j_colsurfb_2023_113123 crossref_primary_10_3390_v13091693 crossref_primary_10_1038_s41467_021_25312_0 crossref_primary_10_1111_tid_13662 crossref_primary_10_1016_j_matt_2021_09_022 crossref_primary_10_3389_fcimb_2021_697876 crossref_primary_10_1016_j_heliyon_2023_e17148 crossref_primary_10_1111_imr_13393 crossref_primary_10_1093_milmed_usab193 crossref_primary_10_1007_s43678_020_00078_4 crossref_primary_10_1016_j_ebiom_2023_104960 crossref_primary_10_1097_INF_0000000000003773 crossref_primary_10_1016_j_jinf_2021_08_003 crossref_primary_10_3389_fimmu_2021_663586 crossref_primary_10_1002_adtp_202100099 crossref_primary_10_1080_14712598_2024_2326647 crossref_primary_10_1002_ccr3_4218 crossref_primary_10_1016_j_matt_2022_03_008 crossref_primary_10_1093_cid_ciab467 crossref_primary_10_1093_cid_ciab468 crossref_primary_10_1016_j_lfs_2021_119251 crossref_primary_10_1093_ofid_ofac436 crossref_primary_10_1080_07391102_2022_2095305 crossref_primary_10_1002_jcu_23160 crossref_primary_10_1002_jmv_28885 crossref_primary_10_3389_fimmu_2021_790469 crossref_primary_10_1007_s10096_022_04474_9 crossref_primary_10_1016_j_lana_2022_100216 crossref_primary_10_1016_j_cct_2021_106652 crossref_primary_10_1136_bmjmed_2022_000352 crossref_primary_10_1073_pnas_2217590120 crossref_primary_10_1073_pnas_2119893119 crossref_primary_10_1126_scitranslmed_abn3041 crossref_primary_10_1038_s41577_023_00858_w crossref_primary_10_1038_s41598_021_89887_w crossref_primary_10_1016_j_idc_2023_03_003 crossref_primary_10_1128_mmbr_00260_24 crossref_primary_10_1002_biot_202300277 crossref_primary_10_1016_j_cell_2022_05_014 crossref_primary_10_1186_s43168_021_00104_8 crossref_primary_10_5582_bst_2021_01227 crossref_primary_10_2147_DDDT_S301173 crossref_primary_10_1038_s41392_021_00653_w crossref_primary_10_1177_0193841X221112547 crossref_primary_10_1093_ofid_ofad354 crossref_primary_10_1097_HS9_0000000000000651 crossref_primary_10_1158_2326_6066_CIR_21_0675 crossref_primary_10_3892_mmr_2021_12498 crossref_primary_10_3390_ijerph18083919 crossref_primary_10_1002_path_5642 crossref_primary_10_3389_fimmu_2021_644850 crossref_primary_10_3390_life12111758 crossref_primary_10_1177_1759720X221116405 crossref_primary_10_1016_j_chom_2021_04_007 crossref_primary_10_3390_cells10071756 crossref_primary_10_1038_s41577_021_00544_9 crossref_primary_10_1097_MOP_0000000000001062 crossref_primary_10_1007_s00103_021_03389_8 crossref_primary_10_1038_s41564_022_01254_1 crossref_primary_10_1055_a_1449_5128 crossref_primary_10_1016_j_intimp_2022_108570 crossref_primary_10_2174_1381612828666220729093340 crossref_primary_10_1080_14787210_2022_2000861 crossref_primary_10_1186_s40249_022_00940_w crossref_primary_10_1038_s41586_022_05514_2 crossref_primary_10_1016_j_antiviral_2021_105147 crossref_primary_10_1097_MOT_0000000000000981 crossref_primary_10_3389_fmolb_2021_670815 crossref_primary_10_7554_eLife_64496 crossref_primary_10_1016_j_heliyon_2024_e31307 crossref_primary_10_1093_jac_dkab321 crossref_primary_10_3390_jcm12082893 crossref_primary_10_1007_s11864_021_00888_3 crossref_primary_10_3389_fimmu_2021_690742 crossref_primary_10_3390_v15091952 crossref_primary_10_1016_j_apsb_2021_05_007 crossref_primary_10_1016_j_gene_2024_148366 crossref_primary_10_1007_s10875_021_01168_3 crossref_primary_10_3390_vaccines9060557 crossref_primary_10_1093_cid_ciac751 crossref_primary_10_1002_jmv_29528 crossref_primary_10_1111_jgs_17126 crossref_primary_10_1177_11795484221119316 crossref_primary_10_1016_j_mayocp_2021_12_002 crossref_primary_10_1186_s12879_023_08341_6 crossref_primary_10_1093_ofid_ofab398 crossref_primary_10_1093_ofid_ofab153 crossref_primary_10_1371_journal_pmed_1003868 crossref_primary_10_1093_ofid_ofab151 crossref_primary_10_1128_AAC_00350_21 crossref_primary_10_1136_bmjopen_2022_069247 crossref_primary_10_3390_life13112121 crossref_primary_10_1016_j_cct_2022_106997 crossref_primary_10_1002_art_41772 crossref_primary_10_1111_nyas_14898 crossref_primary_10_3390_healthcare10010042 crossref_primary_10_1111_ajt_16449 crossref_primary_10_1080_23744235_2021_1940271 crossref_primary_10_1089_mab_2021_0004 crossref_primary_10_1016_j_chom_2021_04_015 crossref_primary_10_1111_1462_2920_15769 crossref_primary_10_3390_v13081487 crossref_primary_10_1093_cid_ciab882 crossref_primary_10_1097_ACI_0000000000000787 crossref_primary_10_1093_cid_ciac724 crossref_primary_10_3390_vaccines9121376 crossref_primary_10_3390_v13081498 crossref_primary_10_1093_ofid_ofac053 crossref_primary_10_1016_j_diagmicrobio_2024_116643 crossref_primary_10_1128_Spectrum_01352_21 crossref_primary_10_1038_s41586_023_06025_4 crossref_primary_10_1007_s12015_022_10477_y crossref_primary_10_1128_spectrum_02560_21 crossref_primary_10_1016_j_clnesp_2021_09_744 crossref_primary_10_1208_s12249_022_02247_3 crossref_primary_10_1164_rccm_202102_0415UP crossref_primary_10_1093_ofid_ofac043 crossref_primary_10_1182_bloodadvances_2023010105 crossref_primary_10_1007_s10875_021_01068_6 crossref_primary_10_1172_JCI151697 crossref_primary_10_1016_j_chom_2021_01_014 crossref_primary_10_3389_fimmu_2022_947174 crossref_primary_10_5320_wjr_v12_i1_1 crossref_primary_10_1155_2021_9822706 crossref_primary_10_3390_v13122424 crossref_primary_10_1038_s41467_024_54732_x crossref_primary_10_1080_14712598_2023_2226326 crossref_primary_10_1002_sim_10286 crossref_primary_10_1128_Spectrum_00472_21 crossref_primary_10_1093_ofid_ofaf542 crossref_primary_10_1016_j_str_2022_02_011 crossref_primary_10_1097_AOG_0000000000004689 crossref_primary_10_1002_jmv_28805 crossref_primary_10_1016_j_medj_2021_02_001 crossref_primary_10_1080_19420862_2020_1854149 crossref_primary_10_3389_fimmu_2023_1112505 crossref_primary_10_1136_bcr_2021_243469 crossref_primary_10_1056_NEJMoa2102685 crossref_primary_10_1016_j_ijid_2021_09_007 crossref_primary_10_1111_irv_13176 crossref_primary_10_1016_j_intimp_2024_113934 crossref_primary_10_1002_dta_3122 crossref_primary_10_1093_eurheartj_ehab697 crossref_primary_10_1177_11786329221127153 crossref_primary_10_1186_s12985_022_01783_5 crossref_primary_10_1056_NEJMoa2107934 crossref_primary_10_1002_advs_202202771 crossref_primary_10_1016_j_jaci_2021_05_029 crossref_primary_10_1172_JCI154987 crossref_primary_10_1016_j_chest_2021_08_003 crossref_primary_10_1080_13543784_2022_2030310 crossref_primary_10_1128_msphere_00230_25 crossref_primary_10_1093_cid_ciab837 crossref_primary_10_1016_j_ijbiomac_2021_07_013 crossref_primary_10_3389_fmed_2020_626796 crossref_primary_10_1002_prot_26140 crossref_primary_10_1093_ajhp_zxab274 crossref_primary_10_1016_j_hoc_2021_03_010 crossref_primary_10_3389_fimmu_2022_855496 crossref_primary_10_1111_vox_13267 crossref_primary_10_1007_s40121_020_00394_3 crossref_primary_10_1039_D1NR03831A crossref_primary_10_1126_scitranslmed_abl7430 crossref_primary_10_3390_medicina58020309 crossref_primary_10_1038_s41418_020_00711_w crossref_primary_10_1093_abt_tbac032 crossref_primary_10_1038_s41467_024_47928_8 crossref_primary_10_1038_s41587_021_01155_4 crossref_primary_10_1038_s41577_020_00480_0 crossref_primary_10_1128_mSphere_00170_21 crossref_primary_10_1007_s40995_022_01400_8 crossref_primary_10_1016_j_jmii_2025_07_007 crossref_primary_10_1016_j_it_2024_06_003 crossref_primary_10_1038_s41584_022_00755_x crossref_primary_10_1093_ofid_ofac080 crossref_primary_10_1016_j_immuni_2022_05_018 crossref_primary_10_1038_s41422_021_00496_8 crossref_primary_10_1007_s40615_021_01193_3 crossref_primary_10_1016_j_chom_2021_02_019 crossref_primary_10_1001_jama_2021_7515 crossref_primary_10_1093_cvr_cvab343 crossref_primary_10_1016_j_antiviral_2024_105898 crossref_primary_10_1002_jmv_27990 crossref_primary_10_1056_NEJMcp2009575 crossref_primary_10_1017_ice_2021_106 crossref_primary_10_1016_j_antiviral_2022_105297 crossref_primary_10_1016_j_mayocp_2022_06_015 crossref_primary_10_1038_s41421_021_00295_w crossref_primary_10_1001_jama_2022_2832 crossref_primary_10_1016_j_immuni_2022_05_005 crossref_primary_10_1002_jcla_70103 crossref_primary_10_1038_s41467_023_40204_1 crossref_primary_10_1089_tmj_2023_0666 crossref_primary_10_3389_fcvm_2021_745906 crossref_primary_10_34067_KID_0002532021 crossref_primary_10_1080_17474086_2023_2192918 crossref_primary_10_1038_s41375_022_01578_1 crossref_primary_10_2196_29638 crossref_primary_10_1001_jamanetworkopen_2021_47331 crossref_primary_10_1007_s15033_021_2684_1 crossref_primary_10_1371_journal_pone_0262657 crossref_primary_10_1186_s12934_021_01576_5 crossref_primary_10_1016_j_ijid_2021_08_044 crossref_primary_10_1007_s10096_020_04138_6 crossref_primary_10_1016_j_banm_2021_02_021 crossref_primary_10_46889_JCMR_2025_6210 crossref_primary_10_1016_j_ejphar_2021_173890 crossref_primary_10_1016_j_ajem_2021_06_076 crossref_primary_10_1016_j_csbj_2022_08_015 crossref_primary_10_3390_medicina59020203 crossref_primary_10_1038_s41591_021_01285_x crossref_primary_10_1093_cid_ciab912 crossref_primary_10_1002_gch2_202100004 crossref_primary_10_1007_s11095_022_03340_9 crossref_primary_10_1128_CMR_00109_21 crossref_primary_10_1016_j_ebiom_2022_103818 crossref_primary_10_7717_peerj_15344 crossref_primary_10_1016_j_clinthera_2021_08_009 crossref_primary_10_1038_s41577_021_00550_x crossref_primary_10_7759_cureus_16477 crossref_primary_10_7759_cureus_19747 crossref_primary_10_1007_s15010_021_01657_y crossref_primary_10_1038_s41586_021_04386_2 crossref_primary_10_1128_AAC_01063_21 crossref_primary_10_1038_s41586_021_03925_1 crossref_primary_10_3390_v13040647 crossref_primary_10_1038_s41392_021_00733_x crossref_primary_10_1056_NEJMc2033787 crossref_primary_10_1002_jac5_1678 crossref_primary_10_1136_thoraxjnl_2021_217561 crossref_primary_10_1093_infdis_jiab407 crossref_primary_10_51847_jwjMRXHjuT crossref_primary_10_1002_cpt_2459 crossref_primary_10_1080_13543784_2021_1901883 crossref_primary_10_1093_cid_ciad088 crossref_primary_10_1038_s41467_025_59870_4 crossref_primary_10_5811_westjem_22_2_53886 crossref_primary_10_1097_RHU_0000000000001733 crossref_primary_10_1038_s41579_024_01036_y crossref_primary_10_3389_fimmu_2023_1270081 crossref_primary_10_3389_fimmu_2023_1125246 crossref_primary_10_1038_s41589_022_01193_2 crossref_primary_10_1021_acs_jcim_4c00334 crossref_primary_10_1016_j_idc_2025_02_005 crossref_primary_10_1124_pharmrev_120_000285 crossref_primary_10_1172_JCI158499 crossref_primary_10_1016_j_conctc_2025_101496 crossref_primary_10_1111_bcp_15992 crossref_primary_10_1038_s41467_022_28766_y crossref_primary_10_1111_tid_70098 crossref_primary_10_1007_s00063_022_00909_5 crossref_primary_10_1007_s11606_022_07603_4 crossref_primary_10_1038_s41467_023_36295_5 crossref_primary_10_3389_fimmu_2021_716940 crossref_primary_10_1016_j_adaj_2021_01_014 crossref_primary_10_1093_jac_dkae045 crossref_primary_10_3389_fmed_2021_604087 crossref_primary_10_3389_fmed_2021_684151 crossref_primary_10_1056_NEJMvcm2007198 crossref_primary_10_1056_NEJMoa2033130 crossref_primary_10_1128_JVI_01110_21 crossref_primary_10_1891_11_T_737 crossref_primary_10_1016_j_isci_2023_106929 crossref_primary_10_1093_oxfimm_iqab003 crossref_primary_10_1016_j_jmii_2023_07_009 crossref_primary_10_3390_v14112475 crossref_primary_10_1007_s40259_022_00529_7 crossref_primary_10_1097_INF_0000000000003263 crossref_primary_10_2478_prilozi_2021_0001 crossref_primary_10_1007_s42485_021_00057_y crossref_primary_10_1097_QCO_0000000000000762 crossref_primary_10_1177_21501327211019282 crossref_primary_10_3389_fcell_2025_1538934 crossref_primary_10_1186_s12967_020_02673_6 crossref_primary_10_1038_s41423_021_00752_2 crossref_primary_10_3389_fimmu_2021_778829 crossref_primary_10_1038_s41586_021_04017_w crossref_primary_10_1016_j_chembiol_2024_03_008 crossref_primary_10_1111_jcpt_13694 crossref_primary_10_1186_s43556_022_00078_z crossref_primary_10_1128_jvi_01223_24 crossref_primary_10_1016_j_cmi_2021_11_007 crossref_primary_10_1016_j_chom_2022_07_016 crossref_primary_10_3389_fimmu_2022_865401 crossref_primary_10_1016_j_amjmed_2022_06_019 crossref_primary_10_1084_jem_20210198 crossref_primary_10_1093_cid_ciab083 crossref_primary_10_1016_j_ijid_2021_06_034 crossref_primary_10_34067_KID_0007722021 crossref_primary_10_1002_jmv_29310 crossref_primary_10_3390_ijms24119589 crossref_primary_10_1111_bcp_14859 crossref_primary_10_3390_ph15070783 crossref_primary_10_4236_health_2021_133023 crossref_primary_10_1002_cpt_2405 crossref_primary_10_18553_jmcp_2022_21469 crossref_primary_10_4049_jimmunol_2100272 crossref_primary_10_2147_DDDT_S359009 crossref_primary_10_1126_scitranslmed_abf1906 crossref_primary_10_15252_embj_2021107985 crossref_primary_10_1016_j_ajpath_2021_03_004 crossref_primary_10_1016_j_coviro_2021_05_007 crossref_primary_10_3390_audiolres12030025 crossref_primary_10_1111_bcp_14849 crossref_primary_10_3389_fphar_2022_983505 crossref_primary_10_1093_infdis_jiac362 crossref_primary_10_3390_transplantology2030028 crossref_primary_10_3390_vaccines10101612 crossref_primary_10_1016_j_cmi_2021_11_022 crossref_primary_10_1093_cei_uxac008 crossref_primary_10_3389_fimmu_2023_1160283 crossref_primary_10_1097_IPC_0000000000001086 crossref_primary_10_1177_21582440221147022 crossref_primary_10_1017_ash_2021_165 crossref_primary_10_1001_jamanetworkopen_2024_12835 crossref_primary_10_1016_j_mayocp_2022_02_009 crossref_primary_10_1126_scitranslmed_abn1252 crossref_primary_10_1016_j_annemergmed_2021_04_036 crossref_primary_10_3390_ijms23147702 crossref_primary_10_1177_01455613221123737 crossref_primary_10_3389_fmed_2021_648005 crossref_primary_10_1186_s12931_020_01581_z crossref_primary_10_1002_rmv_2314 crossref_primary_10_1007_s00296_021_04905_4 crossref_primary_10_1002_advs_202101166 crossref_primary_10_1128_jvi_01551_21 crossref_primary_10_14423_SMJ_0000000000001374 crossref_primary_10_1371_journal_pone_0288391 crossref_primary_10_1016_j_pharma_2023_04_005 crossref_primary_10_3390_v14091860 crossref_primary_10_1038_s41551_020_00660_2 crossref_primary_10_1038_s41467_022_32551_2 crossref_primary_10_1038_s41591_021_01278_w crossref_primary_10_5501_wjv_v13_i1_88660 crossref_primary_10_3390_microbiolres15010028 crossref_primary_10_7326_M22_0924 crossref_primary_10_3390_pathogens11101201 crossref_primary_10_1002_rmv_2347 crossref_primary_10_1126_scitranslmed_adn0396 crossref_primary_10_1017_cts_2023_679 crossref_primary_10_3390_su17114814 crossref_primary_10_1007_s13205_022_03281_5 crossref_primary_10_3389_fimmu_2022_834942 crossref_primary_10_1016_j_nurpra_2021_02_010 crossref_primary_10_1002_advs_202406980 crossref_primary_10_1007_s13238_021_00871_6 crossref_primary_10_6028_jres_126_010 crossref_primary_10_1002_jmv_28029 crossref_primary_10_1007_s15010_022_01833_8 crossref_primary_10_3390_v13020173 crossref_primary_10_3390_ijms222111869 crossref_primary_10_1002_hon_3086 crossref_primary_10_1016_j_omtm_2021_05_004 crossref_primary_10_3389_fimmu_2023_1116131 crossref_primary_10_3390_ph15081002 crossref_primary_10_3390_ijms22041963 crossref_primary_10_3389_fimmu_2022_980698 crossref_primary_10_1128_spectrum_02706_21 crossref_primary_10_1016_j_coph_2021_11_006 crossref_primary_10_1097_MD_0000000000032191 crossref_primary_10_1016_j_imj_2021_08_001 crossref_primary_10_1080_0886022X_2021_1876730 crossref_primary_10_1126_scitranslmed_abi8452 crossref_primary_10_3389_fimmu_2022_993754 crossref_primary_10_1016_j_cll_2021_10_004 crossref_primary_10_1186_s12879_024_09563_y crossref_primary_10_53126_MEB39551 crossref_primary_10_1016_j_cll_2021_10_008 crossref_primary_10_1016_j_jamda_2021_11_029 crossref_primary_10_3389_fmolb_2022_930931 crossref_primary_10_3390_jcm11051412 crossref_primary_10_1186_s12985_023_01973_9 crossref_primary_10_1080_14728222_2021_1953475 crossref_primary_10_3390_microorganisms10122490 crossref_primary_10_1002_ygh2_455 crossref_primary_10_1017_dmp_2022_15 crossref_primary_10_3390_vaccines9080886 crossref_primary_10_1016_j_chom_2022_08_003 crossref_primary_10_1080_14767058_2021_1903426 crossref_primary_10_3390_jcm11247452 crossref_primary_10_1002_cpt_2420 crossref_primary_10_1111_jog_15338 crossref_primary_10_1016_j_chembiol_2021_05_019 crossref_primary_10_1016_j_coviro_2021_12_015 crossref_primary_10_2217_rme_2020_0189 crossref_primary_10_1111_ajt_16843 crossref_primary_10_1002_cti2_1319 crossref_primary_10_1371_journal_ppat_1009925 crossref_primary_10_1007_s40121_021_00487_7 crossref_primary_10_3389_fimmu_2021_758154 crossref_primary_10_3389_fimmu_2022_980435 crossref_primary_10_1016_j_chom_2022_08_010 crossref_primary_10_1080_20477724_2021_2024030 crossref_primary_10_1053_j_ajkd_2020_12_003 crossref_primary_10_30802_AALAS_CM_21_000011 crossref_primary_10_3390_v13081642 crossref_primary_10_3892_mmr_2022_12779 crossref_primary_10_3389_fimmu_2021_675679 crossref_primary_10_1016_j_cct_2022_106822 crossref_primary_10_1016_j_cell_2021_03_036 crossref_primary_10_1111_sji_13098 crossref_primary_10_1016_j_cllc_2022_10_004 crossref_primary_10_1038_s41421_022_00510_2 crossref_primary_10_1093_infdis_jiad287 crossref_primary_10_1093_ofid_ofab255 crossref_primary_10_1016_j_immuni_2021_06_003 crossref_primary_10_1016_j_jcvp_2023_100158 crossref_primary_10_1093_infdis_jiad286 crossref_primary_10_1093_ofid_ofab254 crossref_primary_10_1002_jmv_28742 crossref_primary_10_1111_tid_13782 crossref_primary_10_1111_trf_17485 crossref_primary_10_1557_s43577_021_00185_2 crossref_primary_10_1016_j_ijpharm_2022_122160 crossref_primary_10_1093_ckj_sfac177 crossref_primary_10_3390_vaccines11030711 crossref_primary_10_1097_IPC_0000000000001130 crossref_primary_10_1111_ajt_16541 crossref_primary_10_1111_ajt_16783 crossref_primary_10_1038_s41467_022_29288_3 crossref_primary_10_1038_s41591_021_01355_0 crossref_primary_10_1038_s41392_022_00954_8 crossref_primary_10_3390_vaccines9111287 crossref_primary_10_1016_j_cell_2021_03_029 crossref_primary_10_36290_vnl_2021_050 crossref_primary_10_1038_s41392_023_01323_9 crossref_primary_10_1128_jvi_00364_22 crossref_primary_10_1016_j_xkme_2022_100470 crossref_primary_10_1002_jmv_27668 crossref_primary_10_1136_jim_2021_002158 crossref_primary_10_1007_s12291_022_01081_5 crossref_primary_10_1016_j_lana_2021_100062 crossref_primary_10_1186_s12879_021_06221_5 crossref_primary_10_1080_13814788_2021_2002295 crossref_primary_10_1186_s41182_025_00767_9 crossref_primary_10_3389_fphar_2020_609212 crossref_primary_10_1136_bmj_n2231 crossref_primary_10_1097_IPC_0000000000001128 crossref_primary_10_3390_pathogens10020114 crossref_primary_10_2147_DDDT_S356951 crossref_primary_10_3390_vaccines13060635 crossref_primary_10_1111_bcp_15089 crossref_primary_10_1016_j_mayocp_2021_03_013 crossref_primary_10_1016_j_mayocp_2021_03_010 crossref_primary_10_3390_v14061326 crossref_primary_10_1007_s00210_022_02265_9 crossref_primary_10_1093_infdis_jiae369 crossref_primary_10_1016_j_jiph_2022_10_010 crossref_primary_10_1128_mbio_00892_25 crossref_primary_10_1038_s41577_022_00784_3 crossref_primary_10_1016_j_immuni_2021_07_008 crossref_primary_10_3390_microorganisms11081985 crossref_primary_10_1093_cid_ciac419 crossref_primary_10_1186_s12951_022_01533_3 crossref_primary_10_1007_s11904_021_00562_1 crossref_primary_10_1038_s41467_021_26354_0 crossref_primary_10_1111_tid_13779 crossref_primary_10_7759_cureus_43094 crossref_primary_10_1093_jpids_piac124 crossref_primary_10_3389_fpubh_2024_1364048 crossref_primary_10_1016_j_jbiotec_2025_09_008 crossref_primary_10_1007_s00508_022_02018_x crossref_primary_10_3390_biom13071095 crossref_primary_10_1080_14740338_2023_2130888 crossref_primary_10_1016_j_bja_2021_07_033 crossref_primary_10_1016_j_ijid_2023_01_012 crossref_primary_10_1016_S2213_2600_21_00263_0 crossref_primary_10_1093_bfgp_elad051 crossref_primary_10_1093_ofid_ofab292 crossref_primary_10_1001_jama_2021_17272 crossref_primary_10_12968_hmed_2021_0112 crossref_primary_10_3389_fmed_2022_806611 crossref_primary_10_1111_bcp_15066 crossref_primary_10_1080_08923973_2021_1993894 crossref_primary_10_1002_jmv_29638 crossref_primary_10_3389_fimmu_2021_782506 crossref_primary_10_1097_AOG_0000000000004700 crossref_primary_10_1097_CRD_0000000000000640 crossref_primary_10_3390_molecules28248092 crossref_primary_10_1016_j_heliyon_2023_e13952 crossref_primary_10_1093_cid_ciab305 crossref_primary_10_1126_sciimmunol_abf8891 crossref_primary_10_1111_imm_13564 crossref_primary_10_1371_journal_pone_0325991 crossref_primary_10_1097_IPC_0000000000001161 crossref_primary_10_1186_s12879_023_08057_7 crossref_primary_10_3390_v17040491 crossref_primary_10_1016_j_immuni_2021_06_018 crossref_primary_10_3390_ijms25010354 crossref_primary_10_1016_j_clim_2022_108959 crossref_primary_10_1155_2021_4078713 crossref_primary_10_1093_ajhp_zxac295 crossref_primary_10_1080_22221751_2021_1878937 crossref_primary_10_1111_resp_14106 crossref_primary_10_1093_cvr_cvab298 crossref_primary_10_15252_embr_202153865 crossref_primary_10_1016_j_diagmicrobio_2022_115656 crossref_primary_10_1038_s41467_021_22926_2 crossref_primary_10_3390_v13071320 crossref_primary_10_3390_v15020438 crossref_primary_10_1056_NEJMoa2033700 crossref_primary_10_1016_j_eclinm_2022_101310 crossref_primary_10_1111_trf_16798 crossref_primary_10_1111_cbdd_13954 crossref_primary_10_53126_MEB40085 crossref_primary_10_1038_s41579_021_00542_7 crossref_primary_10_3389_fmed_2020_596587 crossref_primary_10_3390_antib10020014 crossref_primary_10_1093_ajhp_zxab183 crossref_primary_10_1177_00185787211073466 crossref_primary_10_1016_j_cell_2021_01_037 crossref_primary_10_3389_fimmu_2023_1147991 crossref_primary_10_1080_15257770_2021_1914851 crossref_primary_10_1128_AAC_01237_21 crossref_primary_10_14348_molcells_2021_0075 crossref_primary_10_1038_s41586_021_03398_2 crossref_primary_10_1016_j_ijpharm_2024_124511 crossref_primary_10_1002_bmc_70132 crossref_primary_10_1097_QAI_0000000000002875 crossref_primary_10_4014_jmb_2110_10029 crossref_primary_10_1080_19420862_2023_2220150 crossref_primary_10_1016_j_clinthera_2024_08_019 crossref_primary_10_1111_cts_13384 crossref_primary_10_3390_pathogens12121408 crossref_primary_10_1097_CND_0000000000000394 crossref_primary_10_3389_fmed_2024_1287836 crossref_primary_10_3389_fphar_2024_1351655 crossref_primary_10_1002_VIW_20200178 crossref_primary_10_1016_j_ymthe_2022_01_024 crossref_primary_10_1038_s41598_021_89013_w crossref_primary_10_1186_s40246_021_00326_3 crossref_primary_10_1093_infdis_jiae192 crossref_primary_10_1002_pmic_202100160 crossref_primary_10_1186_s12985_024_02304_2 crossref_primary_10_1007_s11033_021_07020_6 crossref_primary_10_1038_s41551_020_00658_w crossref_primary_10_1111_all_16333 crossref_primary_10_1016_S1473_3099_23_00393_6 crossref_primary_10_1002_jcb_30017 crossref_primary_10_1111_ctr_14245 crossref_primary_10_1126_science_abh1766 crossref_primary_10_1016_j_kint_2022_01_022 crossref_primary_10_1021_acscentsci_1c01205 crossref_primary_10_3390_v15061391 crossref_primary_10_1007_s40121_021_00515_6 crossref_primary_10_1093_cid_ciab968 crossref_primary_10_3390_life12010130 crossref_primary_10_1007_s11033_021_06819_7 crossref_primary_10_1021_acscentsci_3c00158 crossref_primary_10_1099_jmm_0_001728 crossref_primary_10_1084_jem_20210554 crossref_primary_10_1177_2632010X241263054 crossref_primary_10_1038_s41564_021_01051_2 crossref_primary_10_1016_j_pcl_2021_05_011 crossref_primary_10_51847_WyyopUKUKF crossref_primary_10_1186_s12967_021_02744_2 crossref_primary_10_26508_lsa_202101322 crossref_primary_10_7326_M22_1503 crossref_primary_10_1097_IPC_0000000000001109 crossref_primary_10_2196_29504 crossref_primary_10_1038_s41598_023_48145_x crossref_primary_10_3390_v16030407 crossref_primary_10_3389_fimmu_2024_1295029 crossref_primary_10_1016_j_arr_2021_101494 crossref_primary_10_1097_QAI_0000000000002837 crossref_primary_10_1002_jmv_27623 crossref_primary_10_1016_j_cell_2021_02_026 crossref_primary_10_3389_fimmu_2021_808932 crossref_primary_10_7759_cureus_14933 crossref_primary_10_1016_j_ajic_2022_09_021 crossref_primary_10_1080_22221751_2021_1902245 crossref_primary_10_3390_v14030650 crossref_primary_10_3390_cells10061412 crossref_primary_10_1002_psp4_12784 crossref_primary_10_1128_AAC_00491_21 crossref_primary_10_1007_s40472_022_00368_z crossref_primary_10_1186_s13578_023_01099_z crossref_primary_10_3390_biomedicines9091186 crossref_primary_10_1111_tid_13724 crossref_primary_10_1208_s12248_025_01043_8 crossref_primary_10_1016_j_ijtb_2021_09_014 crossref_primary_10_1016_j_cellsig_2022_110559 crossref_primary_10_1111_jgs_17090 crossref_primary_10_3389_fpubh_2021_690017 crossref_primary_10_1002_advs_202402975 crossref_primary_10_1001_jamanetworkopen_2023_9702 crossref_primary_10_1016_j_ajem_2021_08_032 crossref_primary_10_1016_j_iac_2022_10_004 crossref_primary_10_1371_journal_ppat_1011680 crossref_primary_10_1111_ctr_14443 crossref_primary_10_26508_lsa_202101116 |
| Cites_doi | 10.1056/NEJMoa2007764 10.3390/tropicalmed5030112 10.1001/jama.2020.10044 10.1172/JCI141772 10.1016/S0140-6736(20)30566-3 10.1001/jama.2020.16349 10.1056/NEJMoa2021436 10.1056/NEJMoa2019014 10.1016/j.cell.2020.02.052 10.1371/journal.pone.0237419 10.1126/science.abe2402 10.1016/S1473-3099(20)30232-2 10.1056/NEJMoa2015301 10.1016/j.intimp.2020.106869 10.1101/2020.08.12.20169359 10.1038/s41591-020-0869-5 10.15585/mmwr.mm6915e3 10.1016/j.jinf.2020.03.004 10.1016/S1473-3099(20)30482-5 10.1101/2020.09.30.318972 10.15252/emmm.202012697 |
| ContentType | Journal Article |
| Contributor | Thammavong, Jon Ramesh, Mayur Shetley, Tara Rosario, Sheila Schwartz, Adam Herrera, Lisa Sachdeva, Yessica Solis, Edilia Wynter, Timothy Bukhman, Yevgeniy Pascual, Ethan Patel, Eva Clapham, Gregg Frishberg, David Ferdosian, Susan Boscia, Joseph Spak, Cedric Jones, Felecia Wallace, Mary Clariday, Laura Kumar, Princy Leonard, Kiara Glassberg, Jeffrey Pitrak, David Ramirez, Noelia Sobh, Nader Purow, Joshua Jackman, Susan Williams, Haley Davis, Steven G Ven, Borady Clemons, Gary Zeno, Brian Thompson, Charles Robinson, Dianna Barefoot, Carita Huang, Howard Burris, Sarah Hurutado-Rodriguez, Mariana Tapson, Victor Thomas, Amy C Cardona, Jose Verma, Omesh Kaufman West, Erica Mohseni, Ramesh Falk, Jeremy Tomi, Rania El Killian, Aaron Gottlieb, Robert Herbert, Corey Malvestutto, Carlos Amin, Faisal Fischer, William Samuelson, Chad Robles, Gina Chen, Peter Shawa, Imad Berg, Anders Wheeler, David Garrett, John Duque, Krizia Coleman, Tanquinisha Fowlks, Allyson Belden, Katherine Liprie, Sam Azizad, Masoud Crystal, Chad Morris, Jason Carino, Giselle Lee, Codie Ingalls |
| Contributor_xml | – sequence: 1 givenname: Faisal surname: Amin fullname: Amin, Faisal – sequence: 2 givenname: Masoud surname: Azizad fullname: Azizad, Masoud – sequence: 3 givenname: Katherine surname: Belden fullname: Belden, Katherine – sequence: 4 givenname: Joseph surname: Boscia fullname: Boscia, Joseph – sequence: 5 givenname: Yevgeniy surname: Bukhman fullname: Bukhman, Yevgeniy – sequence: 6 givenname: Jose surname: Cardona fullname: Cardona, Jose – sequence: 7 givenname: Peter surname: Chen fullname: Chen, Peter – sequence: 8 givenname: Paul surname: Cook fullname: Cook, Paul – sequence: 9 givenname: Chad surname: Crystal fullname: Crystal, Chad – sequence: 10 givenname: Mike surname: Dougan fullname: Dougan, Mike – sequence: 11 givenname: William surname: Fischer fullname: Fischer, William – sequence: 12 givenname: Jeffrey surname: Glassberg fullname: Glassberg, Jeffrey – sequence: 13 givenname: Robert surname: Gottlieb fullname: Gottlieb, Robert – sequence: 14 givenname: Corey surname: Herbert fullname: Herbert, Corey – sequence: 15 givenname: Howard surname: Huang fullname: Huang, Howard – sequence: 16 givenname: Gregory surname: Huhn fullname: Huhn, Gregory – sequence: 17 givenname: Jeffery surname: Kingsley fullname: Kingsley, Jeffery – sequence: 18 givenname: Princy surname: Kumar fullname: Kumar, Princy – sequence: 19 givenname: Anuj surname: Malik fullname: Malik, Anuj – sequence: 20 givenname: Carlos surname: Malvestutto fullname: Malvestutto, Carlos – sequence: 21 givenname: Patrick surname: Milligan fullname: Milligan, Patrick – sequence: 22 givenname: Bharat surname: Mocherla fullname: Mocherla, Bharat – sequence: 23 givenname: Ramesh surname: Mohseni fullname: Mohseni, Ramesh – sequence: 24 givenname: Jason surname: Morris fullname: Morris, Jason – sequence: 25 givenname: Ramesh surname: Nathan fullname: Nathan, Ramesh – sequence: 26 givenname: David surname: Pitrak fullname: Pitrak, David – sequence: 27 givenname: Joshua surname: Purow fullname: Purow, Joshua – sequence: 28 givenname: Mayur surname: Ramesh fullname: Ramesh, Mayur – sequence: 29 givenname: Yessica surname: Sachdeva fullname: Sachdeva, Yessica – sequence: 30 givenname: Adam surname: Schwartz fullname: Schwartz, Adam – sequence: 31 givenname: Imad surname: Shawa fullname: Shawa, Imad – sequence: 32 givenname: Nader surname: Sobh fullname: Sobh, Nader – sequence: 33 givenname: Valentina surname: Stosor fullname: Stosor, Valentina – sequence: 34 givenname: Charles surname: Thompson fullname: Thompson, Charles – sequence: 35 givenname: Omesh surname: Verma fullname: Verma, Omesh – sequence: 36 givenname: Erica surname: Kaufman West fullname: Kaufman West, Erica – sequence: 37 givenname: David surname: Wheeler fullname: Wheeler, David – sequence: 38 givenname: Michael surname: Winnie fullname: Winnie, Michael – sequence: 39 givenname: Brian surname: Zeno fullname: Zeno, Brian – sequence: 40 givenname: Anders surname: Berg fullname: Berg, Anders – sequence: 41 givenname: Antonina surname: Caudill fullname: Caudill, Antonina – sequence: 42 givenname: Gregg surname: Clapham fullname: Clapham, Gregg – sequence: 43 givenname: Jeremy surname: Falk fullname: Falk, Jeremy – sequence: 44 givenname: David surname: Frishberg fullname: Frishberg, David – sequence: 45 givenname: Lisa surname: Herrera fullname: Herrera, Lisa – sequence: 46 givenname: Niree surname: Hindoyan fullname: Hindoyan, Niree – sequence: 47 givenname: Susan surname: Jackman fullname: Jackman, Susan – sequence: 48 givenname: Tanyalak surname: Parimon fullname: Parimon, Tanyalak – sequence: 49 givenname: Ethan surname: Pascual fullname: Pascual, Ethan – sequence: 50 givenname: Victor surname: Tapson fullname: Tapson, Victor – sequence: 51 givenname: Sam surname: Torbati fullname: Torbati, Sam – sequence: 52 givenname: Tanzira surname: Zaman fullname: Zaman, Tanzira – sequence: 53 givenname: Timothy surname: Wynter fullname: Wynter, Timothy – sequence: 54 givenname: Gina surname: Robles fullname: Robles, Gina – sequence: 55 givenname: Sheila surname: Rosario fullname: Rosario, Sheila – sequence: 56 givenname: Lissette surname: Sanchez fullname: Sanchez, Lissette – sequence: 57 givenname: Borady surname: Ven fullname: Ven, Borady – sequence: 58 givenname: Sarah surname: Burris fullname: Burris, Sarah – sequence: 59 givenname: Giselle surname: Carino fullname: Carino, Giselle – sequence: 60 givenname: Laura surname: Clariday fullname: Clariday, Laura – sequence: 61 givenname: Tanquinisha surname: Coleman fullname: Coleman, Tanquinisha – sequence: 62 givenname: Steven G surname: Davis fullname: Davis, Steven G – sequence: 63 givenname: Krizia surname: Duque fullname: Duque, Krizia – sequence: 64 givenname: Rania El surname: Tomi fullname: Tomi, Rania El – sequence: 65 givenname: Susan surname: Ferdosian fullname: Ferdosian, Susan – sequence: 66 givenname: Allyson surname: Fowlks fullname: Fowlks, Allyson – sequence: 67 givenname: Brittany surname: Garcia fullname: Garcia, Brittany – sequence: 68 givenname: John surname: Garrett fullname: Garrett, John – sequence: 69 givenname: Marcus surname: Holmes fullname: Holmes, Marcus – sequence: 70 givenname: Mariana surname: Hurutado-Rodriguez fullname: Hurutado-Rodriguez, Mariana – sequence: 71 givenname: Nazia surname: Iram fullname: Iram, Nazia – sequence: 72 givenname: Felecia surname: Jones fullname: Jones, Felecia – sequence: 73 givenname: Aaron surname: Killian fullname: Killian, Aaron – sequence: 74 givenname: Kiara surname: Leonard fullname: Leonard, Kiara – sequence: 75 givenname: Janet surname: Jerrow fullname: Jerrow, Janet – sequence: 76 givenname: Blake surname: Johnson fullname: Johnson, Blake – sequence: 77 givenname: Katalin surname: Martits-Chalangari fullname: Martits-Chalangari, Katalin – sequence: 78 givenname: Adriana surname: Palacios fullname: Palacios, Adriana – sequence: 79 givenname: Eva surname: Patel fullname: Patel, Eva – sequence: 80 givenname: Noelia surname: Ramirez fullname: Ramirez, Noelia – sequence: 81 givenname: Dianna surname: Robinson fullname: Robinson, Dianna – sequence: 82 givenname: Chad surname: Samuelson fullname: Samuelson, Chad – sequence: 83 givenname: Cedric surname: Spak fullname: Spak, Cedric – sequence: 84 givenname: Edilia surname: Solis fullname: Solis, Edilia – sequence: 85 givenname: Jon surname: Thammavong fullname: Thammavong, Jon – sequence: 86 givenname: Amy C surname: Thomas fullname: Thomas, Amy C – sequence: 87 givenname: Mary surname: Wallace fullname: Wallace, Mary – sequence: 88 givenname: Carita surname: Barefoot fullname: Barefoot, Carita – sequence: 89 givenname: Meredith surname: Benfield fullname: Benfield, Meredith – sequence: 90 givenname: Gary surname: Clemons fullname: Clemons, Gary – sequence: 91 givenname: Tina surname: Fowler fullname: Fowler, Tina – sequence: 92 givenname: Tara surname: Shetley fullname: Shetley, Tara – sequence: 93 givenname: Haley surname: Williams fullname: Williams, Haley – sequence: 94 givenname: Janet surname: Bourque fullname: Bourque, Janet – sequence: 95 givenname: Melissa surname: Comeaux fullname: Comeaux, Melissa – sequence: 96 givenname: David surname: Guillory fullname: Guillory, David – sequence: 97 givenname: Brandi surname: Ingalls fullname: Ingalls, Brandi – sequence: 98 givenname: Codie surname: Lee fullname: Lee, Codie – sequence: 99 givenname: Sam surname: Liprie fullname: Liprie, Sam – sequence: 100 givenname: Summer surname: Moss fullname: Moss, Summer |
| Copyright | Copyright © 2020 Massachusetts Medical Society. All rights reserved. Copyright © 2020 Massachusetts Medical Society. Copyright © 2020 Massachusetts Medical Society. All rights reserved. 2020 Massachusetts Medical Society |
| Copyright_xml | – notice: Copyright © 2020 Massachusetts Medical Society. All rights reserved. – notice: Copyright © 2020 Massachusetts Medical Society. – notice: Copyright © 2020 Massachusetts Medical Society. All rights reserved. 2020 Massachusetts Medical Society |
| CorporateAuthor | BLAZE-1 Investigators |
| CorporateAuthor_xml | – name: BLAZE-1 Investigators |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7RV 7X7 7XB 8AO 8C1 8FE 8FH 8FI ABUWG AFKRA AN0 AZQEC BBNVY BEC BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ GUQSH HCIFZ K0Y LK8 M0R M0T M1P M2M M2O M2P M7P MBDVC NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS PSYQQ Q9U 7X8 5PM |
| DOI | 10.1056/NEJMoa2029849 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Nursing & Allied Health Database Health & Medical Collection ProQuest Central (purchase pre-March 2016) ProQuest Pharma Collection Public Health Database ProQuest SciTech Collection ProQuest Natural Science Journals Hospital Premium Collection ProQuest Central (Alumni) ProQuest Central UK/Ireland British Nursing Database ProQuest Central Essentials Biological Science Collection (subscription) eLibrary Curriculum ProQuest Central Natural Science Collection ProQuest One ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student Research Library Prep (ProQuest) SciTech Premium Collection New England Journal of Medicine Biological Sciences Consumer Health Database Healthcare Administration Database Medical Database Psychology Database Research Library Science Database (subscription) Biological Science Database Research Library (Corporate) ProQuest Nursing and Allied Health Premium ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China One Psychology ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Psychology Research Library Prep ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials elibrary ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing New England Journal of Medicine ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences ProQuest Health & Medical Research Collection Health Research Premium Collection Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection ProQuest Research Library ProQuest Central (New) ProQuest Public Health ProQuest Biological Science Collection ProQuest Central Basic ProQuest Science Journals ProQuest Family Health ProQuest One Academic Eastern Edition British Nursing Index with Full Text ProQuest Health Management ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest Psychology Journals ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic ProQuest One Psychology MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7RV name: Nursing & Allied Health Database url: https://search.proquest.com/nahs sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1533-4406 |
| EndPage | 237 |
| ExternalDocumentID | PMC7646625 33113295 10_1056_NEJMoa2029849 NJ202101213840307 |
| Genre | Original Article Clinical Trial, Phase II Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
| GrantInformation_xml | – fundername: NCATS NIH HHS grantid: UL1 TR001422 – fundername: ; |
| GroupedDBID | - 0R 0WA 123 1VV 29N 2KS 2WC 34G 39C 4 4.4 53G 55 5RE 7FN 7RV 7X7 85S 8AO 8C1 8FE 8FH 8FI 9M8 AACLI AAEJM AAIKC AALRV AAPBV AAQQT AARDX AAUTI AAWTL ABACO ABEHJ ABFLS ABIVO ABOCM ABPPZ ABPTK ABQIJ ABUWG ABWJO ACGFS ACGOD ACJLH ACNCT ACPRK ACPVT ACRZS ADBBV ADBIT ADCBC AENEX AETEA AFFNX AFHKK AFKRA AGFXO AGNAY AHMBA AJJEV AJVPN ALMA_UNASSIGNED_HOLDINGS AN0 AQUVI AZQEC BBAFP BBNVY BCU BENPR BES BHPHI BKEYQ BKNYI BLC BNQBC BPHCQ BVXVI C45 CJ0 CO CS3 DCD DU5 DWQXO DZ EBS ET EX3 F5P FD8 FM. FYUFA GJ GNUQQ GUQSH HCIFZ HZ I4R IH2 K-O KM KOO L7B LK8 M0R M0T M1P M2M M2O M2P M7P MQT MVM N9A NAPCQ NEJ O9- OK1 OMK OVD P-O P-S P2P PADUT PCD PQEST PQQKQ PQUKI PRINS PROAC PSQYO QJJ RHI RWL RXW S10 S6N SJFOW SJN TAE TAF TEORI TN5 TUQ TWZ UCV UKR UMD VQA W2G WH7 WOQ WOW X X7M XJT XYN XZL YCJ YNT YRY YZZ ZA5 ZHY ZR0 --- -DZ -ET -~X .-4 .55 .CO .GJ 0R~ 36B AAMNW AAYXX ABBLC ABCQX ABDQB ABJNI ABUFD ACKOT ACPFK ADRHT ADUKH AERZD AFFHD AGHSJ BYPQX CCPQU CITATION HF~ HMCUK HZ~ N4W PHGZM PHGZT PJZUB PPXIY PQGLB PSYQQ UKHRP YFH YR2 YR5 YYP ZCA ZVN ~KM AFOSN ALIPV CGR CUY CVF ECM EIF NPM UIG 7XB BEC K0Y MBDVC PKEHL Q9U 7X8 PUEGO 186 5PM H13 |
| ID | FETCH-LOGICAL-c473t-5b21b9566f0f49b1b9ea4120cd6415a7a5f7badf2a7dc7550e497d1c1e42f89d3 |
| IEDL.DBID | DCD |
| ISICitedReferencesCount | 1000 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000613533100008&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0028-4793 1533-4406 |
| IngestDate | Tue Nov 04 02:00:56 EST 2025 Fri Sep 05 10:22:42 EDT 2025 Sat Nov 29 14:37:48 EST 2025 Thu Apr 03 07:09:24 EDT 2025 Sat Nov 29 03:02:09 EST 2025 Tue Nov 18 22:29:49 EST 2025 Tue Dec 21 14:39:01 EST 2021 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Language | English |
| License | http://www.nejmgroup.org/legal/terms-of-use.htm Copyright © 2020 Massachusetts Medical Society. This article is made available via the PMC Open Access Subset for unrestricted re-use, except commercial resale, and analyses in any form or by any means with acknowledgment of the original source. These permissions are granted for the duration of the Covid-19 pandemic or until revoked in writing. Upon expiration of these permissions, PMC is granted a license to make this article available via PMC and Europe PMC, subject to existing copyright protections. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c473t-5b21b9566f0f49b1b9ea4120cd6415a7a5f7badf2a7dc7550e497d1c1e42f89d3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Article-2 ObjectType-Feature-1 content type line 23 ObjectType-Undefined-3 A list of the BLAZE-1 investigators is provided in the Supplementary Appendix, available at NEJM.org. Drs. Chen and Nirula contributed equally to this article. |
| ORCID | 0000-0002-5330-1718 0000-0001-8376-8709 |
| OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC7646625 |
| PMID | 33113295 |
| PQID | 2479469285 |
| PQPubID | 40644 |
| PageCount | 9 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_7646625 proquest_miscellaneous_2455844509 proquest_journals_2479469285 pubmed_primary_33113295 crossref_primary_10_1056_NEJMoa2029849 crossref_citationtrail_10_1056_NEJMoa2029849 mms_nejm_10_1056_NEJMoa2029849 |
| PublicationCentury | 2000 |
| PublicationDate | 2021-01-21 |
| PublicationDateYYYYMMDD | 2021-01-21 |
| PublicationDate_xml | – month: 01 year: 2021 text: 2021-01-21 day: 21 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: Boston |
| PublicationTitle | The New England journal of medicine |
| PublicationTitleAlternate | N Engl J Med |
| PublicationYear | 2021 |
| Publisher | Massachusetts Medical Society |
| Publisher_xml | – name: Massachusetts Medical Society |
| References | Farooqi, F, Dhawan, N, Morgan, R, Dinh, J, Nedd, K, Yatzkan, G (r012) 2020; 5 Chen, J, Qi, T, Liu, L (r020) 2020; 80 Beigel, JH, Tomashek, KM, Dodd, LE (r005) 2020; 383 Stebbing, J, Krishnan, V, de Bono, S (r010) 2020; 12 Sterne, JAC, Murthy, S, Diaz, JV (r014) 2020; 324 Joyner, MJ, Senefeld, JW, Klassen, SA (r015) 2020 Hoffmann, M, Kleine-Weber, H, Schroeder, S (r018) 2020; 181 Jones, BE, Brown-Augsburger, PL, Corbett, KS (r019) 2020 Spinner, CD, Gottlieb, RL, Criner, GJ (r007) 2020; 324 He, X, Lau, EHY, Wu, P (r021) 2020; 26 Cavalcanti, AB, Zampieri, FG, Rosa, RG (r004) 2020; 383 Tabata, S, Imai, K, Kawano, S (r001) 2020; 20 Baum, A, Ajithdoss, D, Copin, R (r017) Zhou, F, Yu, T, Du, R (r023) 2020; 395 (r013) 2020; 383 Li, L, Zhang, W, Hu, Y (r016) 2020; 324 r003 Jehi, L, Ji, X, Milinovich, A (r002) 2020; 15 Liu, Y, Yan, L-M, Wan, L (r022) 2020; 20 Sims, JT, Krishnan, V, Chang, C-Y (r008) Bronte, V, Ugel, S, Tinazzi, E (r009) Goldman, JD, Lye, DCB, Hui, DS (r006) 2020; 383 Dastan, F, Saffaei, A, Haseli, S (r011) 2020; 88 Kim, L, Garg, S, O’Halloran, A (r024) Li L (e_1_3_5_17_2) 2020; 324 e_1_3_5_16_2 Beigel JH (e_1_3_5_6_2) 2020; 383 Dastan F (e_1_3_5_12_2) 2020; 88 e_1_3_5_14_2 Goldman JD (e_1_3_5_7_2) 2020; 383 Sterne JAC (e_1_3_5_15_2) 2020; 324 Liu Y (e_1_3_5_23_2) 2020; 20 Tabata S (e_1_3_5_2_2) 2020; 20 Sims JT (e_1_3_5_9_2) 2020 Farooqi F (e_1_3_5_13_2) 2020; 5 Kim L (e_1_3_5_25_2) 2020 Spinner CD (e_1_3_5_8_2) 2020; 324 He X (e_1_3_5_22_2) 2020; 26 Bronte V (e_1_3_5_10_2) 2020 Stebbing J (e_1_3_5_11_2) 2020; 12 Zhou F (e_1_3_5_24_2) 2020; 395 Baum A (e_1_3_5_18_2) 2020 e_1_3_5_20_2 Hoffmann M (e_1_3_5_19_2) 2020; 181 Jehi L (e_1_3_5_3_2) 2020; 15 e_1_3_5_4_2 Chen J (e_1_3_5_21_2) 2020; 80 Cavalcanti AB (e_1_3_5_5_2) 2020; 383 33378610 - N Engl J Med. 2020 Dec 30;384(2) |
| References_xml | – ident: r017 article-title: REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters. publication-title: Science – ident: r003 article-title: Garg SKL, Kim L, Whitaker M, et al. Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019 — COVID-NET, 14 states, March 1–30, 2020. MMWR Morb Mortal Wkly Rep 2020;69: 458 - 464 – volume: 181 start-page: 271.e8 issue: 2 year: 2020 end-page: 280.e8 ident: r018 article-title: SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. publication-title: Cell – volume: 88 start-page: 106869 year: 2020 end-page: 106869 ident: r011 article-title: Promising effects of tocilizumab in COVID-19: a non-controlled, prospective clinical trial. publication-title: Int Immunopharmacol – volume: 383 start-page: 1813 year: 2020 end-page: 1826 ident: r005 article-title: Remdesivir for the treatment of Covid-19 — final report. publication-title: N Engl J Med – volume: 26 start-page: 672 year: 2020 end-page: 675 ident: r021 article-title: Temporal dynamics in viral shedding and transmissibility of COVID-19. publication-title: Nat Med – volume: 80 start-page: e1 issue: 5 year: 2020 end-page: e6 ident: r020 article-title: Clinical progression of patients with COVID-19 in Shanghai, China. publication-title: J Infect – year: 2020 ident: r015 article-title: Effect of convalescent plasma on mortality among hospitalized patients with COVID-19: initial three-month experience. ;(https://www.medrxiv.org/content/10.1101/2020.08.12.20169359v1) – ident: r024 article-title: Risk factors for intensive care unit admission and in-hospital mortality among hospitalized adults identified through the U.S. Coronavirus Disease 2019 (COVID-19)-Associated Hospitalization Surveillance Network (COVID-NET). publication-title: Clin Infect Dis – volume: 395 start-page: 1054 year: 2020 end-page: 1062 ident: r023 article-title: Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. publication-title: Lancet – volume: 15 start-page: e0237419 issue: 8 year: 2020 end-page: e0237419 ident: r002 article-title: Development and validation of a model for individualized prediction of hospitalization risk in 4,536 patients with COVID-19. publication-title: PLoS One – volume: 383 start-page: xxx year: 2020 end-page: xxx ident: r013 article-title: Dexamethasone in hospitalized patients with Covid-19 — preliminary report. publication-title: N Engl J Med ;The RECOVERY Collaborative Group – volume: 324 start-page: 1 year: 2020 end-page: 13 ident: r014 article-title: Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. publication-title: JAMA – year: 2020 ident: r019 article-title: LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection. ;(https://www.biorxiv.org/content/10.1101/2020.09.30.318972v3) – ident: r009 article-title: Baricitinib restrains the immune dysregulation in severe COVID-19 patients. publication-title: J Clin Invest – volume: 383 start-page: 1827 year: 2020 end-page: 1837 ident: r006 article-title: Remdesivir for 5 or 10 days in patients with severe Covid-19. publication-title: N Engl J Med – volume: 324 start-page: 1048 year: 2020 end-page: 1057 ident: r007 article-title: Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial. publication-title: JAMA – volume: 383 start-page: 2041 year: 2020 end-page: 2052 ident: r004 article-title: Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19. publication-title: N Engl J Med – volume: 324 start-page: 460 year: 2020 end-page: 470 ident: r016 article-title: Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. publication-title: JAMA – volume: 20 start-page: 656 year: 2020 end-page: 657 ident: r022 article-title: Viral dynamics in mild and severe cases of COVID-19. publication-title: Lancet Infect Dis – volume: 20 start-page: 1043 year: 2020 end-page: 1050 ident: r001 article-title: Clinical characteristics of COVID-19 in 104 people with SARS-CoV-2 infection on the Diamond Princess cruise ship: a retrospective analysis. publication-title: Lancet Infect Dis – ident: r008 article-title: Characterization of the cytokine storm reflects hyperinflammatory endothelial dysfunction in COVID-19. publication-title: J Allergy Clin Immunol – volume: 12 start-page: e12697 issue: 8 year: 2020 end-page: e12697 ident: r010 article-title: Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients. publication-title: EMBO Mol Med – volume: 5 start-page: E112 year: 2020 end-page: E112 ident: r012 article-title: Treatment of severe COVID-19 with tocilizumab mitigates cytokine storm and averts mechanical ventilation during acute respiratory distress: a case report and literature review. publication-title: Trop Med Infect Dis – volume: 383 start-page: 1813 year: 2020 ident: e_1_3_5_6_2 article-title: Remdesivir for the treatment of Covid-19 — final report. publication-title: N Engl J Med doi: 10.1056/NEJMoa2007764 – volume: 5 start-page: E112 year: 2020 ident: e_1_3_5_13_2 article-title: Treatment of severe COVID-19 with tocilizumab mitigates cytokine storm and averts mechanical ventilation during acute respiratory distress: a case report and literature review. publication-title: Trop Med Infect Dis doi: 10.3390/tropicalmed5030112 – volume: 324 start-page: 460 year: 2020 ident: e_1_3_5_17_2 article-title: Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. publication-title: JAMA doi: 10.1001/jama.2020.10044 – year: 2020 ident: e_1_3_5_10_2 article-title: Baricitinib restrains the immune dysregulation in severe COVID-19 patients. publication-title: J Clin Invest doi: 10.1172/JCI141772 – volume: 395 start-page: 1054 year: 2020 ident: e_1_3_5_24_2 article-title: Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. publication-title: Lancet doi: 10.1016/S0140-6736(20)30566-3 – year: 2020 ident: e_1_3_5_9_2 article-title: Characterization of the cytokine storm reflects hyperinflammatory endothelial dysfunction in COVID-19. publication-title: J Allergy Clin Immunol – volume: 324 start-page: 1048 year: 2020 ident: e_1_3_5_8_2 article-title: Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial. publication-title: JAMA doi: 10.1001/jama.2020.16349 – volume: 324 start-page: 1 year: 2020 ident: e_1_3_5_15_2 article-title: Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. publication-title: JAMA – ident: e_1_3_5_14_2 doi: 10.1056/NEJMoa2021436 – volume: 383 start-page: 2041 year: 2020 ident: e_1_3_5_5_2 article-title: Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19. publication-title: N Engl J Med doi: 10.1056/NEJMoa2019014 – volume: 181 start-page: 271.e8 issue: 2 year: 2020 ident: e_1_3_5_19_2 article-title: SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. publication-title: Cell doi: 10.1016/j.cell.2020.02.052 – volume: 15 start-page: e0237419 issue: 8 year: 2020 ident: e_1_3_5_3_2 article-title: Development and validation of a model for individualized prediction of hospitalization risk in 4,536 patients with COVID-19. publication-title: PLoS One doi: 10.1371/journal.pone.0237419 – year: 2020 ident: e_1_3_5_18_2 article-title: REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters. publication-title: Science doi: 10.1126/science.abe2402 – volume: 20 start-page: 656 year: 2020 ident: e_1_3_5_23_2 article-title: Viral dynamics in mild and severe cases of COVID-19. publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(20)30232-2 – volume: 383 start-page: 1827 year: 2020 ident: e_1_3_5_7_2 article-title: Remdesivir for 5 or 10 days in patients with severe Covid-19. publication-title: N Engl J Med doi: 10.1056/NEJMoa2015301 – volume: 88 start-page: 106869 year: 2020 ident: e_1_3_5_12_2 article-title: Promising effects of tocilizumab in COVID-19: a non-controlled, prospective clinical trial. publication-title: Int Immunopharmacol doi: 10.1016/j.intimp.2020.106869 – ident: e_1_3_5_16_2 doi: 10.1101/2020.08.12.20169359 – volume: 26 start-page: 672 year: 2020 ident: e_1_3_5_22_2 article-title: Temporal dynamics in viral shedding and transmissibility of COVID-19. publication-title: Nat Med doi: 10.1038/s41591-020-0869-5 – ident: e_1_3_5_4_2 doi: 10.15585/mmwr.mm6915e3 – volume: 80 start-page: e1 issue: 5 year: 2020 ident: e_1_3_5_21_2 article-title: Clinical progression of patients with COVID-19 in Shanghai, China. publication-title: J Infect doi: 10.1016/j.jinf.2020.03.004 – year: 2020 ident: e_1_3_5_25_2 article-title: Risk factors for intensive care unit admission and in-hospital mortality among hospitalized adults identified through the U.S. Coronavirus Disease 2019 (COVID-19)-Associated Hospitalization Surveillance Network (COVID-NET). publication-title: Clin Infect Dis – volume: 20 start-page: 1043 year: 2020 ident: e_1_3_5_2_2 article-title: Clinical characteristics of COVID-19 in 104 people with SARS-CoV-2 infection on the Diamond Princess cruise ship: a retrospective analysis. publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(20)30482-5 – ident: e_1_3_5_20_2 doi: 10.1101/2020.09.30.318972 – volume: 12 start-page: e12697 issue: 8 year: 2020 ident: e_1_3_5_11_2 article-title: Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients. publication-title: EMBO Mol Med doi: 10.15252/emmm.202012697 – reference: 33378610 - N Engl J Med. 2020 Dec 30;384(2): |
| SSID | ssj0000149 |
| Score | 2.7413135 |
| Snippet | In a phase 2 trial, outpatients with Covid-19 who received a single infusion of a 2800-mg dose of the neutralizing antibody LY-CoV555 had a greater reduction... Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (Covid-19), which is most frequently mild yet can be severe and... BackgroundSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (Covid-19), which is most frequently mild yet can be... Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (Covid-19), which is most frequently mild yet can be severe and... |
| SourceID | pubmedcentral proquest pubmed crossref mms |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 229 |
| SubjectTerms | Adolescent Adult Aged Aged, 80 and over Antibodies Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - adverse effects Antibodies, Neutralizing - administration & dosage Antibodies, Neutralizing - adverse effects Asymptomatic Clinical outcomes Coronaviridae Coronaviruses COVID-19 COVID-19 - drug therapy COVID-19 - virology Disease Dose-Response Relationship, Drug Double-Blind Method Emergency medical care Female Hospitalization - statistics & numerical data Humans Immunologic Factors - administration & dosage Immunologic Factors - adverse effects International organizations Intravenous administration Male Medical research Middle Aged Monoclonal antibodies Original Outpatients Pandemics Patients Placebos Reverse Transcriptase Polymerase Chain Reaction Ribonucleic acid Risk factors RNA RNA, Viral - blood SARS-CoV-2 - genetics SARS-CoV-2 - isolation & purification Severe acute respiratory syndrome coronavirus 2 Severity of Illness Index Statistical analysis Viral Load - drug effects Young Adult |
| SummonAdditionalLinks | – databaseName: Science Database (subscription) dbid: M2P link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LT9wwELZ4VBWXvkuXUmSkqqdaxI4fyalarQo9wIJKi-gpSmxHXcQmlGQrwa9nJutddqvSS2-RPJYcz9jz9DeEvDfaJcKUkjnEv5RxaVnhbMQE18qlwum4C7idHZrhMDk_T09CwK0JZZWzO7G7qF1tMUa-Jzoo9FQk6tPVL4ZdozC7GlporJJ1sGw4lnQdiZMF-Khg_oYIUsDYBJ2_h53m61wgADnCaC7opNXxuPmbufln1eSCGtp_-r8_8Iw8CQYo7U8l5jlZ8dUL8vgopNhfkoPT_tdTNqjPmKBDP-kCIbeg32i_akdF7W7o4Q8cVkrRUUWPJ22AZm0oxnTpAF_2MZ6-It_3P38bfGGh2wKz0sQtU4XgBXhLuoxKmRbw7XPJRWSdBiWfm1yVpshdKXLjrAHHxsvUOG65l6JMUhe_JmtVXfk3hHrtI1XGzkc2AXPNJ1o6fDZl8wR2W7se-Tjb78wGKHLsiHGZdSlxpbMl9vTIhzn51RSD4yHCHWBeVvmL8UME2zPeZOGsNtk9Y3pkdz4MpwxTJ3nl6wnSKLDUJFhXPbI5FYP5UuKYg0ufwmyzJCBzAkTwXh6pRj87JG-jpQYHdOvfy3pLNgRW0kQcjtA2WWuvJ_4deWR_t6PmeqcT-Tv4ZwWI priority: 102 providerName: ProQuest |
| Title | SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 |
| URI | https://nejm.org/doi/full/10.1056/NEJMoa2029849 https://www.ncbi.nlm.nih.gov/pubmed/33113295 https://www.proquest.com/docview/2479469285 https://www.proquest.com/docview/2455844509 https://pubmed.ncbi.nlm.nih.gov/PMC7646625 |
| Volume | 384 |
| WOSCitedRecordID | wos000613533100008&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVBGY databaseName: New England Journal of Medicine Current customDbUrl: eissn: 1533-4406 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: DCD dateStart: 19900101 isFulltext: true titleUrlDefault: https://www.nejm.org/medical-index providerName: Massachusetts Medical Society – providerCode: PRVPQU databaseName: Consumer Health Database customDbUrl: eissn: 1533-4406 dateEnd: 20250909 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: M0R dateStart: 19800103 isFulltext: true titleUrlDefault: https://search.proquest.com/familyhealth providerName: ProQuest – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1533-4406 dateEnd: 20250909 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: 7X7 dateStart: 19800103 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: Healthcare Administration Database customDbUrl: eissn: 1533-4406 dateEnd: 20250909 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: M0T dateStart: 19800103 isFulltext: true titleUrlDefault: https://search.proquest.com/healthmanagement providerName: ProQuest – providerCode: PRVPQU databaseName: Nursing & Allied Health Database customDbUrl: eissn: 1533-4406 dateEnd: 20250909 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: 7RV dateStart: 19800103 isFulltext: true titleUrlDefault: https://search.proquest.com/nahs providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Biological Science Database (NC LIVE) customDbUrl: eissn: 1533-4406 dateEnd: 20250909 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: M7P dateStart: 19800103 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1533-4406 dateEnd: 20250909 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: BENPR dateStart: 19800103 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Psychology Database customDbUrl: eissn: 1533-4406 dateEnd: 20250909 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: M2M dateStart: 19800103 isFulltext: true titleUrlDefault: https://www.proquest.com/psychology providerName: ProQuest – providerCode: PRVPQU databaseName: Public Health Database customDbUrl: eissn: 1533-4406 dateEnd: 20250909 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: 8C1 dateStart: 19800103 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest – providerCode: PRVPQU databaseName: Research Library customDbUrl: eissn: 1533-4406 dateEnd: 20250909 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: M2O dateStart: 19800103 isFulltext: true titleUrlDefault: https://search.proquest.com/pqrl providerName: ProQuest – providerCode: PRVPQU databaseName: Science Database customDbUrl: eissn: 1533-4406 dateEnd: 20250909 omitProxy: false ssIdentifier: ssj0000149 issn: 0028-4793 databaseCode: M2P dateStart: 19800103 isFulltext: true titleUrlDefault: https://search.proquest.com/sciencejournals providerName: ProQuest |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3db9MwED-tG0K88M0oG1WQEE9YSxx_5bHLNnhYu6obVXmKEtsRnWiC1hQJ_np8blqtwIR4-SmSz5Jj38nnO_t3AG-lMIrKkhGD_JcsLjUpjA4JjQQ3CTUi9gG3ybkcDtV0mox24Gj9Fqay13OfwEeLxgj0ujr8EdaGr3OKlOEs6cAe6hqq8Ul6cosvqvV325BRS6r5R_etTagzny_-5l_-fk3y1r5z9ui_R_wYHrYuZtBf6cQT2LHVU7g_aJPoz-DDZX98SdJ6QmgwtEsf6vjpdrCgXzWzojY_gvPP2Mw5D2ZVcLFsWvLVRYBR2yDFt3skSp7Dp7PTq_QjaespEM1k3BBe0Khw5yFRhiVLCvdtcxbRUBvhtvFc5ryURW5KmkujpTu6WJZIE-nIMlqqxMQvYLeqK_sSAitsyMvY2FAr55BZJZjBh1E6V-5fhenC-_UEZ7olG8eaF18zn_TmItuanC6824h_W7Fs3CXYc6uV4ZzfJXC4XsistcZFRj2NfkIV78KbTbOzI0yO5JWtlyjDnS_GnP_Uhf3Vum-GEseRO7Qnrrfc0oiNAHJ0b7dUsy-eq1sKJtwR89W_xn0ADyjelgkjZyaHsNvcLO1ruKe_N7PFTQ86cjxBnEqPyqFKox7sHZ8OR-OetwKHg3Ds8QqRDjxeeBwhytEv0zb_tA |
| linkProvider | Massachusetts Medical Society |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Nb9QwEB21BVEufFMWSjEScMJq4vgjOaBqtVBadbtUtFTlFBLbUbdik9JkQeVH8RvrySbLLqLceuAWyZMoiZ_Hz-PxG4AXSpqQqYxTg_qXPMg0TY32KPOlMBEzMqgDbod9NRiER0fR3gL8as_CYFpl6xNrR20KjTHydVZLoUcsFBun3yhWjcLd1baExgQWO_b8h1uylW-237r-fcnY5ruD3hZtqgpQzVVQUZEyP3WrApl5GY9Sd20T7jNPG-kms0QlIlNpYjKWKKOVI_CWR8r42recZWFkAvfcRbjGUVkMUwXZ3oxcVUO3m4hVo-npOMY6VrYvEoaC5yjbOTMHLo5G5d_o7Z9ZmjPT3ubt_-2H3YFbDcEm3cmIuAsLNr8HN3abFIL78H6_-3Gf9opDysjAjutAz083f5NuXg3TwpyT_mdsFkKQYU4-jKtGerYkGLMmPTy5SP3oAXy6ks94CEt5kdtHQKy0nsgCYz0dOjpqQ8kNHgvTSeh6V5oOvG77N9aN1DpW_Pga11v-QsZzcOjAq6n56URj5DLDNQeWOLcno8sMVlssxI0vKuPfQOjA82mz8yK4NZTkthijjXBMlDv22IGVCeymrxIEvh-wyN2t5gA5NUCF8vmWfHhcK5UryaVbYD_-92s9g-Wtg91-3N8e7DyBmwyzhjzfuYtVWKrOxvYpXNffq2F5tlYPNwJfrhquF6_NY0I |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1bb9MwFD7aBpr2wv1SGMNIwBNWY8eX5AGhqqMwrSvTBtN4ContaEU0GUsKGj-NX4edOqVFjLc98BbJJ1ESfz7-fHz8HYCnUuiIypxh7fQvWZgrnGkVYEoE1zHVImwCbkdDORpFx8fx_gr8bM_CuLTK1ic2jlqXysXIu7SRQo9pxLu5T4vY3x68Ov2KXQUpt9PaltOYQWTXnH-3y7fq5c627etnlA5ev--_xb7CAFZMhjXmGSWZXSGIPMhZnNlrkzJCA6WFndhSmfJcZqnOaSq1kpbMGxZLTRQxjOZRrEP73FW4IhmnTrd_LzhYkK7y1NtHr7y-p-UbXVflvkypEz93Ep4L8-HqZFL9jer-mbG5MAUOrv_PP-8GXPPEG_VmI-UmrJjiFqzv-dSC2_DmsHdwiPvlEaZoZKZNAOiHnddRr6jHWanP0fCja-aco3GB3k1rL0lbIRfLRn13ohGT-A58uJTPuAtrRVmY-4CMMAHPQ20CFVmaaiLBtDsuptLI9rTQHXjR9nWivAS7qwTyJWlSAbhIlqDRgedz89OZ9shFhlsWOElhPk8uMthscZF4H1Ulv0HRgSfzZutd3JZRWphy6my4ZajMssoO3JtBcP4qYUhISGN7t1wC59zAKZcvtxTjk0bBXAom7ML7wb9f6zGsW5Qmw53R7kPYoC6ZKCDWi2zCWn02NY_gqvpWj6uzrWbkIfh02Wj9BcZZbAU |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=SARS-CoV-2+Neutralizing+Antibody+LY-CoV555+in+Outpatients+with+Covid-19&rft.jtitle=The+New+England+journal+of+medicine&rft.au=Chen%2C+Peter&rft.au=Nirula%2C+Ajay&rft.au=Heller%2C+Barry&rft.au=Gottlieb%2C+Robert+L&rft.date=2021-01-21&rft.pub=Massachusetts+Medical+Society&rft.issn=0028-4793&rft.eissn=1533-4406&rft.volume=384&rft.issue=3&rft.spage=229&rft.epage=237&rft_id=info:doi/10.1056%2FNEJMoa2029849&rft.externalDocID=NJ202101213840307 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0028-4793&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0028-4793&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0028-4793&client=summon |